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A STUDY ON FACTORS INFLUENCING THE 
SUCCESS OF THROMBOLYSIS BY STREPTOKINASE IN 
ACS - STEMI PATIENTS IN CMCH GENERAL MEDICINE 
DEPARTMENT 
INTRODUCTION 
 
Coronary heart disease (CHD) is a health epidemic present 
worldwide. Results of mortality data from Global Burden of Diseases Studies: 
CVD especially CAD are important cause of death in India. 
Major causes of death around the world: cardiovascular disease, 
Cancer, Chronic respiratory diseases, HIV/AIDS, TB, Diabetes.  
                Worldwide 30 % of all deaths are attributed to CVD,  out of which 
more than half  are caused by CHD.  It is expected that in future the number 
will grow due to lifestyle changes in developing countries. Of those dying 
from CVD, 80% are in developing countries .  
Myocardial infarction in India: 
The incidence of MI  in India is steadily increasing over the past few 
decades. Rural to urban ratio in rise in MI cases is around 2:9. This could 
probably be due to migration from rural to urban cities. Another major 
problem is the occurrence of MI at a younger age in the Indian population. 
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STEMI is an emergency due to  acute total occlusion of an epicardial 
coronary artery , most often due to atherosclerotic plaque rupture / erosion and 
subsequent thrombus formation. Compared to UA / NSTEMI, STEMI is 
associated with a higher in -hospital and 30 day morbidity and mortality.  Left 
untreated, the mortality rate of STEMI can exceed 30% and the presence of 
mechanical complications (papillary muscle rupture, ventricular septal defect, 
and free wall rupture) increases the mortality rate to 90% .  
Keys to treatment of STEMI  include rapid recognition and diagnosis, 
co ordinated mobilization of health care resources, and prompt reperfusion 
therapy. Mortality is directly related to total ischaemia time. 
Thrombolysis by fibrinolytic agents is still the preferred mode of 
treatment in India . Only 15%  to 20%  of patients with MI are able to undergo 
primary PCI, available in only a few tertiary hospitals in the city limits. 
Several factors contribute to success of re perfusion in a case of STEMI – age, 
sex, time taken from onset of pain to treatment, co morbidities like diabetes 
and systemic hypertension, lifestyle changes like smoking, whether AWMI 
OR IWMI ,etc. So, in the following study, the influence of each of these 
factors on the success of thrombolysis by Inj.Streptokinase in STEMI patients 
have been analysed and correlated with the data obtained from subjects from 
similar studies.  
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AIM OF THE STUDY 
 
1. TO STUDY THE VARIOUS MODIFIABLE AND NON-
MODIFIABLE FACTORS INFLUENCING THE SUCCESS OF 
THROMBOLYSIS IN ACS – STEMI PATIENTS  
2. COMPARING THE STUDY WITH SIMILAR STUDIES 
CONDUCTED BEFORE IN FAMOUS INSTITUTIONS  
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REVIEW OF LITERATURE 
 
ACUTE CORONARY SYNDROME: 
Acute coronary syndrome (ACS) is a term for the common end result, 
acute myocardial ischemia. It includes STEMI, NSTEMI and Unstable 
Angina. 
ANATOMY OF CORONARY ARTERIES: 
The coronary arteries arise from the coronary sinuses  and supply 
the myocardium.  
There are two coronary arteries, a left coronary and a right coronary. 
They arise from the left and right aortic sinuses respectively.  
LEFT MAIN CORONARY ARTERY: 
The left coronary artery divides into the left circumflex artery (LCX), 
which passes over the left atrio-ventricular groove, and the left anterior 
descending artery (LAD), which courses towards the apex in the anterior inter-
ventricular groove.  
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Branches of Left coronary artery : 
1.  Left anterior descending artery –  
It can be divided into proximal, mid and distal segments and this helps 
to differentiate the names of its various small branches: 
Branches: 
x Septal perforators: course to the right towards the septum, Named as 
S1, S2 etc 
x Diagonal branches: course to the left on the anterolateral wall of the left 
ventricle. Named as D1, D2 etc..  
Segments: 
x Proximal: from the origin the first diagonal branch (D1) (although some 
authors use the first septal perforator (S1) as the landmark) 
x Mid: from the origin of D1 to half the distance from the D1 origin to 
the apex. 
x Distal: distal to half the distance from the D1 origin to the apex. 
Relations: 
The LAD lies in the epicardial fat within the anterior inter-ventricular 
septum 1:  
x Inferior: myocardium 
x Superior: pericardium   
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Supply: 
It supplies the anterolateral myocardium and apex with one of its 
branches supplying the anterior two-thirds of the inter- ventricular septum.  
Variant anatomy:   
x dual left anterior descending coronary artery 2:  two left anterior 
descending coronary arteries (one usually shorter in length) that are 
both situated in the anterior inter-ventricular groove. 
x It is important to know of this variation when planning surgical 
vascularisation3 
Circumflex artery: 
The artery travels in the left atrio-ventricular groove between the left 
ventricle and left atrium. The artery is located in the epicardium. 
The circumflex artery gives off up to three obtuse marginal 
branches and may give off a left postero-lateral branch and may supply the 
inferior inter-ventricular artery. 
Supply - Branches of the circumflex artery supply the lateral and postero-
lateral walls of the left ventricle.  
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Variant anatomy: 
x In a left-dominant circulation, the circumflex artery supplies the 
inferior inter-ventricular artery instead of the right coronary artery. 
(RCA)   
x In a co-dominant circulation, both the circumflex artery and RCA 
supply the inferior inter-ventricular artery (or a duplicated inferior 
inter-ventricular artery) 
x The RCA supplying the inferior inter-ventricular artery and the 
circumflex artery supplying a large left postero-lateral branch has also 
been considered co-dominant 
x The circumflex artery may arise separately off the left coronary cusp 
from the LAD (i.e. no left main coronary artery )  the circumflex artery 
may have an aberrant origin off the right coronary cusp. 
Ramus intermedius: 
The ramus intermedius   results from trifurcation of the LMCA. It is 
present in 15% - 30% of the population.  
It can have a course similar to the obtuse marginal branches of the LCX 
artery or the diagonal branches of the LAD artery and thus can supply either 
the anterior or medial aspect of the heart.  
In practice, even if there is not a true trifurcation, some cardiologists 
may term a prominent early branching (high origin) obtuse marginal artery,  a 
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ramus branch if it supplies the territory of small diagonal branches since there 
is an inverse relationship between the size of the ramus intermedius and the 
size and distribution of the diagonal branches. 
RIGHT CORONARY ARTERY: 
The right coronary artery (RCA) is one of the two main coronary 
arteries. 
Origin: 
The RCA originates from the right coronary sinus .  
Course: 
The RCA passes to the right in the right atrio-ventricular groove, along 
the anterior to inferior surface of the heart. 
x In people with right dominant circulation (seen in the majority of 
people), the RCA passes anteriorly to become the inf inter-ventricular 
artery 
x In people with left dominant circulation the RCA peters out usually as 
an acute marginal artery and the inferior inter-ventricular artery usually 
arises from the left circumflex artery. 
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Branches: 
x Conus artery (in 60%) 
x Sinus artery (60%) 
x Acute marginal arteries (designated AM1, 2, etc) 
x Atrio-venticular nodal artery 
x Terminal branches (in right dominant circulation) 
x Inferior inter-ventricular artery also known as the  posterior descending 
artery.   
x Posterior left ventricular branch (PLV or PLB) 
x In left dominant hearts, the RCA usually peters out as an acute marginal 
branch 
Supply: 
x Conus artery: pulmonary outflow tract 
x Sinus artery: sinoatrial (SA) node 
x Acute marginal arteries: anterior wall of the right ventricle 
x Atrio-ventricular nodal artery: atrio-venticular (SA) node 
x Terminal branches (in right dominant circulation) 
x PDA: inferior wall of the right ventricle and the inferior 1/3 of the inter-
ventricular septum (the latter defining coronary dominance). 
x PLV: inferior wall of the left ventricle 
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Variant Anatomy: 
A. Variations in origin 
x From the aorta at or above the sino-tubular junction 
x From the left coronary sinus or LCA where the proximal RCA takes 
a 'malignant' inter-arterial course in which the vessel is prone to 
extrinsic compression 
x In up to 50% of cases there are separate ostia for the RCA and conus 
artery from the sinus or aorta 
B.  Variations in branching 
x PDA and PLV as terminal branches 
x PDA as the only terminal branch (in which the PLV is supplied by the 
LCx) 
x Terminates as an acute marginal branch (in left dominant circulations) 
C.  Variations in course 
x Intra-atrial course  
x Inter-arterial course  
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INFERIOR INTERVENTRICULAR ARTERY: 
The inferior inter-ventricular artery is an artery that extends along the 
inferior inter-ventricular sulcus. The artery supplies the posterior third of the 
inter-ventricular septum through posterior septal perforating arteries. 
The inferior inter-ventricular artery can anastomose with the anterior 
inter-ventricular artery, a branch of the  LAD. It can also anastomose with the 
LAD through each vessel's respective septal perforators. 
The vessel that supplies this artery establishes the coronary 
artery dominance of the heart. In a right-dominant system (89.1%), the right 
circumflex artery supplies it. In a left-dominant system (8.4%), the left 
circumflex supplies it. 
DEFINITIONS: 
UNSTABLE ANGINA: 
Unstable angina is usually due to reduced blood supply to myocardium 
due to  coronary artery athero-thrombosis but it does not result in any 
myocardial necrosis. 
STEMI: 
Two of the following three criteria should be present as per the Classic 
WHO criteria for  acute MI : (1) a history indicative of coronary ischemia for 
atleast more than 30 minutes (2) evolutionary changes on serial ECGs 
indicative of myocardial infarction, and (3) a rise and fall in serum cardiac 
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markers suggestive of necrosis of myocardium. Only two of the three criteria 
are needed for diagnosis .  
NSTEMI: 
If the patient did not have ST elevation or Q waves in ECG, and the 
cardiac enzymes are elevated, the patient was diagnosed as having NSTEMI. 
MYOCARDIAL INFARCTION - STEMI:  
The 30-day mortality rate from myocardial infarction is 30%, with 
more deaths occurring before arrival of patient to a hospital  Approximately 1 
out of 25 patients who survives the initial period dies in the first year after 
myocardial infarction.  
PATHOPHYSIOLOGY:   
STEMI usually occurs when coronary blood flow decreases all of a 
sudden following a thrombotic occlusion of a coronary artery which was  
previously affected by atherosclerosis. In most cases, STEMI occurs when the 
surface of an atherosclerotic plaque becomes disrupted and conditions favor 
thrombogenesis and a thrombus develops at the site of vessel injury.  
PLAQUES: 
The atherosclerotic plaques of STEMI patients are composed of fibrous 
tissue of varying density with overlying thrombus. Coronary arterial thrombi 
responsible for STEMI are usually 1cm in length; stick to the luminal surface 
of an artery; and contain platelets, fibrin, erythrocytes ,and leukocytes. 
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PLAQUE DISRUPTION: 
Atherosclerotic plaques which are prone to disruption express 
metalloproteinase enzymes in increased amounts which in turn degrade 
components of the protective extracellular matrix. 
Caused by: 
1. Activated macrophages and mast cells  
2. Stresses caused by intraluminal pressure, increased tone of coronary 
arteries, increased heart rate and disruption of nutrient vessels.  
Plaque disruption occurs followed by exposure of thrombogenic 
substances and the coronary artery lumen is obstructed by platelet aggregates, 
fibrin, and RBCs. They in turn produce an extensive thrombus filling a large 
segment of the coronary artery.  
Disruption of plaques is now considered to underlie most acute 
coronary syndromes. Complete occlusive thrombi results in  a large zone of 
necrosis involving nearly full thickness of the ventricular wall and typically 
produce ST elevation on the ECG.  
14 
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PATHOPHYSIOLOGY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Atherosclerotic plaque in vessel 
Plaque rupture due to 
metalloproteinase enzymes, stress, 
incr. vessel tone, 
Exposure of thrombogenic intima 
Aggregation of platelets , fibrin and 
RBCs 
Complete occlusion of coronary vessel 
Ischaemia and infarct of distal 
myocardium – MI 
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ECG changes: 
QRS changes seen due to alteration in the sequence of depolarization. 
The typical change is the evolution of Q waves in the leads directly over the 
infarct area — the Q-wave infarction.  
Other abnormalities of the QRS complex - diminution in “R” wave 
height and notching of the QRS. They are seen in UA or NSTEMI. 
PATHOLOGY: 
Time Of Occlusion Permanent Occlusion/ No Reperfusion 
GROSS HISTOLOGIC 
12 HRS No change Wavy fibres 
24 – 48 hrs Pallor – yellow  Hypereosinophilic 
fibers, PMNs at borders 
3 – 5 days  Yellow center, 
hyperemic borders 
Large number of PMNs 
at border coagulation 
necrosis, loss of nuclei 
6 – 10 days  Yellow, depressed 
central infarct, tan-red 
margins 
Mummified fibers in 
center, macrophage 
phagocytosis + 
granulation tissue at 
borders 
10 – 14 days  Gray red borders, 
encroaching into the 
large central tan-yellow 
infarct  
Marked granulation 
tissue, collagen 
deposition, sub-
endocardialmyocyte 
sparing 
2 – 8 weeks  Gelatin like to gray-
white scar, greater 
healing near border zone 
areas.  
Collagen deposition 
with prominent large 
capillaries 
17 
 
So this shows the importance of early thrombolysis by drugs or 
mechanical methods to save as much of the cardiac myocytes as possible. 
CLINICAL PRESENTATION: 
The most common presenting complaint in STEMI is pain .It occurs 
even at rest.   
Types of description: 
heavy, squeezing, and crushing, sometimes stabbing or burning 
Radiation to: arms, especially right arm, and the abdomen, back, lower jaw, 
and neck , to the occipital area but never radiates below the umbilicus.  
Pain is usually accompanied by weakness, sweating, nausea, vomiting, 
anxiousness, and a sense of impending doom. The pain may start when the 
patient is at rest.  When it occurs during exertion, it does not subside with rest, 
as against angina pectoris. 
Less common presentations: 
1. Painless MI - Painless STEMIs is more common in diabetes mellitus, 
and in elderly. In the elderly, STEMI may present as acute dyspnoea, 
which may progress to pulmonary edema.  
2. Sudden loss of: consciousness, a state of confusion, a sensation of 
profound weakness, the appearance of an irregular heart rate, evidence 
of peripheral embolism, or merely fall in blood pressure. 
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Differential diagnosis: 
a. Acute pericarditis,  
b. Pulmonary embolism, 
c.  Acute aortic dissection,  
d. Costo-chondritis, and 
e. Gastrointestinal disorders.  
PHYSICAL FINDINGS: 
Chest pain with perspiration almost always suggestive of STEMI. 
 Tachycardia and hypertension common in AWMI (sympathetic nervous 
system hyperactivity),  
 Bradycardia and hypotension common in IWMI (evidence of 
parasympathetic hyperactivity)  
Auscultatory findings: 
x Soft S1.  
x S3 and S4 indicating ventricular dysfunction. 
x Paradoxical splitting of S2. 
x A transient mid-systolic or late systolic apical murmur due to 
dysfunction of the mitral valve apparatus may be present. 
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x Pericardial - friction rub. 
x Carotid - pulse decreased in volume. 
x Temperature elevations up to 38°C observed in the 1st week  after  
STEMI 
x Blood pressure: in transmural infarction, systolic pressure falls by 
nearly 10–15 mmHg from the pre-infarction state. 
LABORATORY FINDINGS: 
The laboratory tests of value in confirming the diagnosis may be 
divided into four groups: 
Electrocardiogram: 
An electrocardiogram (ECG or EKG) is a graphic recording of electric 
potentials generated by the heart.  
Diagnostic ECG criteria for STEMI: 
x Peaked upright “T” waves is the 1st ECG manifestation of myocardial 
injury. 
x  When ST elevations reach threshold values in two or more 
anatomically contiguous leads, a diagnosis of STEMI can be made.  
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1.  ST segment elevation two consecutive ECG leads  
- Men > 40 yrs , “ST segment”  elevation at the J point > 2mm in leads 
V2 and V3 , > 1 mm in all leads  
- Men < 40 yrs , “ST segment” elevation at the J point > 2.5 mm in leads 
V2 and V3  
- In women , “ST segment” elevation at the J point > 1.5mm in leads V2 
and V3 > 1 mm in all leads 
2.   New onset LBBB also is indicative of large anterior wall MI, with 
 worse prognosis 
Criteria for ST – segment elevation for prior LBBB or RV – Paced 
Rhythm : (Sgarbossa’s criteria) 
a. ST – Elevation > 1 mm in the presence of a positive QRS complex 
(concordant with the QRS) (5 points ) 
b. ST – Elevation > 5 mm in the presence of a negative QRS complex 
(discordant with the QRS) (3 points)  
c. ST – segment depression > 1 mm in V1 & V3 (2 points)  
A total of more than or equal to 3 points is suggestive of acute MI, in 
the presence of “LBBB”, without need for further investigations . 
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OTHER SCORING SYSTEMS USING ECG: 
A.  Sclarovsky – Birnbaum score:  
Grade I  :  Tall , peaked , symmetrical T waves  
Grade II  :  Slope elevation of ST segment  
Grade III  : Distortion of the terminal QRS complex in the form of J 
 point elevation of > 50 % of the preceding R or loss of 
 normal S waves. 
B.  Anderson Wilkins score –  
To assess acuteness of ischaemia. It is calculated as  4 (no. of leads 
with tall T yes / abnormal Q no) + 3 (no. of leads with neither yes) + 2 (no. of 
leads with both yes) + 1 (no. of leads with tall T no / abnormal Q yes) divided 
by total no. of leads with ST elevation.  
WELLENS SYNDROME: 
Patients presents with chest pain . ECG during chest pain is normal. 
Following chest pain, symmetric and deep T wave inversion or biphasic T 
waves may develop in V2 – V6, in the pain free period. There are no 
pathological Q waves. This is due to tight proximal LAD stenosis. 
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LOCALISATION OF LESION BASED ON ECG: 
Site of infarct ST - elevation ST- depression 
Antero – septal  V1-V4, qRBBB II, III, aVF 
Antero-lateral I, aVL, V2-V4 + V5-V6 
Antero-apical V4-V6, occasionally II, 
III, aVF 
aVL 
Lateral wall  I, Avl, V5-V6  
Extensive anterolateral I , Avl, V1-V6, aVR>V1   
Infero-posterior  II, III, aVF I, Avl, V2, V3  
Posterior wall  V7-V9 V1-V3 
 
1. ANTERIOR WALL MI:  
ECG-characteristics 
x ST-elevation in leads “ V1-V6, I and aVL”. Maximum elevation in 
“V3”, maximal depression in “III” 
x Later: pathological “ Q” wave in the precordial leads “V2 to V4-V5”. 
Characteristics of proximal LAD occlusion 
¾ “ST-segment” elevation in V1 (>2.5 mm) or “RBBB” with a 
pathologic “Q” wave or both  
¾ “ST-segment” depression (>1 mm) in “II, III and aVF” 
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Characteristics of distal LAD occlusion 
¾ Little “ST-segment depression” (<= 1 mm) or elevation in “II, III, and 
aVF”  
2.  SEPTAL WALL MI:  
“QS” in “V1 and V2.” Later the septum-Q in “V5 and V6” disappears.  
3.  LATERAL WALL MI :  
“ST elevation” in “I, aVL, V5 and V6” 
4. INFERIOR WALL MI:  
“ST elevation” in “II, III and Avf” 
This part of the heart lies on the diaphragm and is supplied by the right 
coronary artery (RCA) in 80% of patients and In the 20% ; the inferior wall is 
supplied by the ramus circumflex (RCX). 
“ST elevation/ depression” in “V4R” help in differentiating a RCA 
from an RCX occlusion. 
Distal RCA occlusion  
¾ “ST segment elevation” in “III” higher than “ST segment elevation” in 
“II” ("the highest elevation points at the culprit")and 
¾ “ST segment depression” in “I, AVL, or both” (>1 mm) 
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Proximal RCA occlusion  
¾ Additional “ST segment elevation” in “V1, V4R or both” 
RCX occlusion  
¾ “ST segment elevation” in “I, AVL, V5, and V6” and 
¾ “ST segment depression” in “V1, V2, and V3” 
5. POSTERIOR WALL MI : 
¾ High R-waves with “ST-depression” in “V1-V3”. 
¾ Posterior MI caused by occlusion of RCA . 
6. RIGHT VENTRICLE MI :  
“ST elevation” in lead “V1”  and high “R/S ratio in V1 “.  
Criteria for Right Ventricular MI  
¾ “ST-elevation” >1 mm in lead “V4” right 
¾ “ST elevation” >1 mm in lead “V1”  
Can be seen after a proximal occlusion of the RCA. 
Differential Diagnosis of ST-Segment Elevations : 
A. Acute pericarditis 
B. Normal variants (including "early repolarization" patterns) 
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C. Left ventricular hypertrophy/left bundle branch block 
D. Acute pulmonary embolism 
E. Brugada patterns (right bundle branch block–like pattern with ST:  
elevations in right precordial leads) 
F. Class 1-C antiarrhythmic drugs 
G. DC -cardioversion 
H.  Hypercalcemia 
I. Hyperkalemia 
J. Hypothermia [J (Osborn) waves] 
K.  Myocarditis 
L. Left ventricle tumor 
M. Ventricular trauma  
CARDIAC ENZYMES: 
Damaged cardiomyocytes release - several proteins in the circulation 
including myoglobin; creatine kinase (CK) and its myocardial band isoenzyme 
(CK-MB); troponins (I and T), aspartate aminotransferase; and lactate 
dehydrogenase. Cardiac troponins have high sensitivity and specificity and are 
currently the preferred biomarkers.  
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CK-MB is the other alternative because of its rapid) appearance and 
disappearance from the blood: 
1) In earlier presentations; 
2) To time the onset of injury; and  
3) To detect re-infarction 
Blood sampling for “biomarker determination” is recommended at hospital 
admission and can be repeated at “6 to 9 hours”, and at “12 to 24 hours”  if the 
clinical suspicion is high. 
Myoglobin: 
Myoglobin is a 17.8-kDa protein that is released from damaged 
myocardial cells. Myoglobin release occurs within hours after the onset on 
infarction, peaks at 1 to 4 hours, and plateaus for about 24 hours. But 
myoglobin should not be used alone for diagnosing MI. 
CK-MB: 
The MB isoenzyme of creatine kinase has highest concentration in 
myocardium.  
CK-MB appears in serum within about 3 hours after the onset of 
infarction, peaks at 12 to 24 hours, and plateaus for about 1 to 3 days.  
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Noncardiac causes of raised CK-MB levels: 
1. In  hypothyroidism,  
2. In extensive skeletal muscle trauma, ( rhabdomyolysis ) 
3. In muscular dystrophies, and  
4. Some neuromuscular disorders. 
Troponins: 
The cardiac troponins regulate the interaction of actin and myosin . 
They are more cardiac specific than CK-MB. 
There are two isoforms of cardiac troponin: T and I. Their levels start to 
rise 3 to 12 hours after the onset of ischemia, peak at 12 to 24 hours, and 
plateau for 8 to 21 days (troponin T) or 7 to 14 days (troponin I). Elevated 
troponin levels indicate pathologically proven necrosis of myocardium and 
poor prognosis in patients with ACS.  
ECHOCARDIOGRAPHY: 
Used as a screening tool because of the ease and safety of the 
procedure. 
USES:-  
a.  Detection of the presence or absence of “wall motion abnormalities” 
help in management decisions.  
b. It is useful in estimation of left ventricular (LV) function  
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c. Identification of RVMI , ventricular aneurysm, pericardial effusion, and 
LV thrombus. 
d.  “Doppler echocardiography” is useful in the detection of  VSD and 
MR, the 2 serious complications of STEMI. 
RADIONUCLIDE IMAGING TECHNIQUES: 
They are used less often than echocardiography because they are more 
cumbersome and lack sensitivity and specificity.  
Myocardial perfusion imaging: 
Done with “[201Tl] or [99mTc]- sestamibi”, which are distributed in 
proportion to myocardial blood flow and concentrated by viable myocardium. 
They reveal a defect ("cold spot") after development of a transmural infarct in 
the 1st few hours. 
Disadvantage: not specific for the diagnosis of acute MI as it cannot 
distinguish acute infarcts from chronic scars.  
Radionuclide ventriculography: done with “[99mTc]-labeled red blood 
cells”, it frequently shows wall motion disorders and reduction in the 
ventricular EF in patients with STEMI.  
Use: In assessing the hemodynamic consequences of infarct and when the 
RV ejection fraction is depressed it suggests RV infarction  
Disadvantage: It is nonspecific, as many cardiac abnormalities show similar 
pattern. 
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MANAGEMENT: 
1. IV:  “NS on D5W” to keep vein patent. 
2. Vital signs: every 1.5 hr until stable, then every 4 hr and as needed. 
3. Monitor: Continuous ECG to watch out for dysrhythmia and “ST 
segment deviation” 
4. Oxygen: Continuous oximetry monitoring at 2 liters/min if stable for 
6 hr,  
5. Medications: 
x Nitroglycerin (NTG): Use sublingual NTG - 0.4 mg every 5 min 
as needed for chest discomfort. Intravenous NTG for - CHF, 
hypertension, or persistent ischemia. 
x Aspirin (ASA; acetylsalicylic acid): If Aspirin not given in the 
ED, chew non -enteric-coated ASA – 162-325 mg. If Aspirin has 
been given, start daily maintenance of  75-162 mg daily 
x Oral P2Y12 Inhibitors: loading dose of 300 mg stat followed by 
75 mg OD of T.clopidogrel. Other agents used are T. prasugrel 
and T. ticagrelor. 
x GP IIb/IIIaInhibitors: used as an alternative to oral P2Y12 
inhibitors especially in those undergoing PCI. 
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x Beta blocker: If not given in the ED, assess for contraindication 
(i.e., bradycardia and hypotension); If given in the ED, continue 
daily dose and optimize as dictated by heart rate and blood 
pressure. 
x Angiotensin-converting enzyme (ACE) inhibitor: Start ACE 
inhibitor orally in patients with “LVEF <40 percent” if the 
following are absent: hypotension (SBP <100 mm Hg or <30 mm 
Hg below baseline) or known contraindications ACEI. 
x Angiotensin receptor blocker (ARB): only in those who cannot 
tolerate ACEI.  
x Pain medications: IV morphine sulfate 2-4 mg with increments of 
2-8 mg IV at 5- to 15-min intervals as needed .  
x Anxiolytics  
x Stool softener 
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REPERFUSION THERAPY: 
It can be done by two methods: 
1.Fibrinolytic drugs  
2.PCI 
Regardless of whether reperfusion is achieved by fibrinolysis or PCI, 
restoration of blood flow in the obstructed coronary artery after the onset of 
symptoms of chest pain, palpitations etc in patients with STEMI, is a key 
factor of short- and long-term outcome.  
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FIBRINOLYTIC AGENTS: 
Classified as fibrin and non-fibrin specific . 
Fibrin specific - streptokinase, anistreplase, urokinase 
Non-fibrin specific - alteplase, reteplase, tenecteplase.  
Streptokinase (a beta -hemolytic streptococcal isolate) still is the most 
frequently employed thrombolytic agent especially in developing world where 
Cath labs at tertiary hospitals for primary PCI is still beyond reach for the 
population at large . 
COMPARISON OF FIBRINOLYTIC DRUGS : 
Characteristic Streptokinase Alteplase Reteplase Tenecteplase 
Dose 
1.5 x 106 U in 
30–60 min 
Up to 100 mg 
in 90 min 
2 x 10 U 
bolus 
0.5 mg/kg 
bolus 
Antigenicity ++ – – – 
Fibrin 
specificity 
– ++ + +++ 
Cost + +++ +++ +++ 
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STREPTOKINASE : 
It was discovered in 1933 by “William Smith Tillett” along with his 
student “Sol Sherry.”  
In 1958, “Sherry “and others started using streptokinase in  MI patients 
which lead to “cure” of the patients . Currently streptokinase is the most 
important drug in the management of  MI especially in developing countries 
like India . 
MECHANISM OF ACTION : 
 The streptococcal substance – fibrinolysin ,  activates the proteinase 
precursor , resulting in its conversion to an active enzyme . The active serum 
proteinase then lyses the fibrin clot. 
INITIAL USE OF STREPTOKINASE : 
a. To treat fibrinous and purulent pleural effusions 
b. Haemothorax 
c. Tuberculous meningitis 
THE GISSI TRIAL : 
GISSI - GruppoItaliano per la - Sperimentazioned : 
ellaStreptochinasinell'Infarto - Miocardico . 
At the GISSI trial ,  the initial report changed the outlook of physicists 
all over  the world  regarding thrombolytic therapy for STEMI. Around 11,806 
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patients from 176 coronary care units in different hospitals were included 
during a period of 17 months ( February 1984 to June 1985) for the study. The 
results showed patients had  higher chance of survival if the time was shorter 
between the symptom onset and the streptokinase infusion .  
The final report of GISSI, published in “The Lancet “after a 12-month 
follow up period, proved the usefulness of streptokinase. There was a 
significant difference in mortality rates between the streptokinase group and 
the non-streptokinase group (controls) at - 12 months.  
 Thus, GISSI succeeded in firmly establishing the efficacy of 
intravenously administered streptokinase. 
OTHER TRIALS : 
GUSTO , GISSI-2 , ISIS-3 TRIAL:  
All three trials compared the efficacy of tissue - plasminogen activator 
(t-PA) with that of streptokinase. 
GUSTO (Global Utilization of - Streptokinase and Tissue Plasminogen 
Activator for Occluded Coronary Arteries) found no - significant difference in: 
mortality rates after 1 month.  
GISSI-2 (GruppoItaliano per so -Studio dellaSopravvienzane: 
ll'InfartoMiocardico) found no significant difference in mortality rates at 6 
months    
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ISIS-3 (Third International Study of Infarct Survival Collaborative 
Group) found no significant differences in mortality rates  
GUSTO-3 and ASSENT (Assessment of the Safety and Efficacy of a 
New -Thrombolytic Regimen), showed no superiority with reteplase, and 
equivalent results with tenecteplase,  
ABSOLUTE CONTRAINDICATIONS : 
a. A history of intra cerebral hemorrhage at any time 
b. A non hemorrhagic stroke or other cerebrovascular event in the last one 
year 
c. Suspicion of aortic dissection 
d. Active internal bleeding 
e. Closed head injury within 3 months 
f. Acute pericarditis  
g. Known structural cerebrovascular lesion – AVMs, aneurysms , tumor 
RELATIVE CONTRAINDICATIONS : 
a. Current use of anticoagulants (international normalized ratio >2) 
b. A recent (<2 weeks) invasive or surgical procedure 
c. Prolonged (>10 min) cardiopulmonary resuscitation 
d. Known bleeding diathesis 
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e. Pregnancy 
f. A hemorrhagic ophthalmic condition (e.g., hemorrhagic diabetic 
retinopathy), 
g. Active peptic ulcer disease 
h. Allergy or previous use of streptokinase 
i. Non-compressible vascular punctures 
j. Uncontrolled hypertension – SBP > 180 mm Hg , DBP > 110 mm Hg  
INFLUENCE OF FACTORS ON THROMBOLYSIS: 
INFLUENCE OF AGE ON THROMBOLYSIS: 
Age is by far the single most important predictor of ultimate survival 
after acute myocardial infarction. In fact, in GUSTO-1 trial, the 24-hour 
mortality for the elderly was 10 times greater than that of the youngest 
patients. This stresses the importance to consider thrombolytic therapy in this 
exceptionally high–risk group. 
A Study on “Acute Coronary Syndrome In Elderly – The Difference,  
Compared With Young In Intensive Care Unit Of A Tertiary Hospital” In 
Western Nepal was done on patients admitted to ICU in the “Manipal 
Teaching Hospital “in the month of “March 2006 to June 2007”. Out of 153 
patients were analyzed - elderly patients ( > 65 yrs ) constituted 51% (78) of 
the study population . The success rate of thrombolysis was lower in elderly 
patients (50%) as compared to young patients (76.9%). The end result of the 
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study was elderly patients are more prone to complications; have less success 
rate for thrombolysis and; have a higher mortality rate when compared to 
young patients.  
INFLUENCE OF SEX ON THROMBOLYSIS: 
Gender does not influence the success rate of thrombolysis. The only 
clinical condition that had increased thrombolytic usage in women compared 
to men was a history of prior myocardial infarction. 
A study  “Gender and acute myocardial infarction: is there a different 
response to thrombolysis?” was conducted by Woodfield SL1, Lundergan CF 
and co . Patency rates and global and regional left ventricular function were 
determined in patients at 90 min and “5 to 7 days” after thrombolytic therapy 
for acuteMI. The results “ninety-minute post thrombolysis” in women and 
men were 39% and 38%, respectively (p = 0.5). Women had more recurrent 
ischemia than men. The conclusion of the study was women do not differ 
significantly from men with regard to early infarct-related artery patency rates 
.Gender was a factor independent of the success and failure rate of 
thrombolysis. 
INFLUENCE OF LIFESTYLE ON THROMBOLYSIS: 
Regular physical activity can produce long term health benefits. Many 
clinical trials have shown that “low physical activity” is an independent and a 
strong risk factor for CVS as well as all-cause mortality. 
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Low physical activity is associated with the following diseases : 
x Coronary - artery disease  
x Cerebrovascular diseases 
x Type II - diabetes mellitus  
x Obesity  
x Depression disorder 
Occupational physical activity can be classified as below: 
i. High physical activity : lots of walking and ; lifting at work ( eg. 
Agricultural work, industrial work)  
ii. Moderate physical activity: walking quite a lot at work; without 
lifting or carrying heavy objects. 
iii. Low physical activity: mostly sedentary work; without much 
walking (eg. Working at office, homemaker) 
Community activity is classified as : 
i. High : “> 30 min” physical activity ( walking , cycling ) per day 
ii. Moderate : exercising between 15 to 30 min per day  
iii. Low : exercising < 15 min per day  
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Effect on thrombolysis: 
Lifestyle has no influence on the result of thrombolysis. 
INFLUENCE OF SMOKING ON THROMBOLYSIS: 
India has approximately 120 million smokers. According to WHO, 12% 
of world’s smokers are in India. Smoking causes 9 lakh deaths per year in 
India. According to 2002 WHO report, 30% of Indian adult males are 
smokers. Among adult females, it is around 3 to 5% .  
Smoking  increases  blood  hematocrit,  fibrinogen levels  and  platelet  
levels  contributing  to  the hypercoagulable state promoting coronary 
thrombosis.  Smokers  are  also  found  to  have  lesser fibrinolytic  activity  
than  nonsmokers. 
Pack years:  
Formula to measure the amount of cigarettes smoked by a person over a 
period of time. It is calculated by total no. of packs of cigarettes smoked per 
day multiplied by the total no. of years the person has smoked.  
Effect on thrombolysis : 
Smokers have lower mortality after acute coronary syndrome than non-
smokers. This is due to the 1 younger age, 2 lower co-morbidity, 3 more 
aggressive treatment and 4 lower risk profile of the smoker. Non-smokers with 
ECG evidence of failed thrombolysis had 40% short-term mortality and had 
higher plasma fibrinogen than current smokers. Lower cardiac mortality in 
40 
 
smokers may probably be due to complete systemic fibrinolysis. The term 
"smoker's paradox" was introduced into scientific discourse more than 25 
years ago following observations that smokers (in comparison to non-
smokers) experience decreased mortality following an acute MI. But recently 
it has been argued that “smoking paradox” is not because of any benefit from 
smoking but simply because smokers are likely to undergo such procedures at 
a much younger age and thus have an average lower comorbidity. The 
paradox, however, has not been demonstrated in those undergoing routine 
early invasive management. 
A study “Lower cardiac mortality in smokers following thrombolysis 
for acute myocardial infarction may be related to more effective fibrinolysis”. 
Of the 332 patients with AMI, 48% were current smokers, 19% previous 
smokers and 33% had never smoked. Results were a successful thrombolysis 
(by 60 mins) was achieved by 44% of current smokers compared with 43% of 
non-smokers. Unsuccessful thrombolysis (by 180 min ) was seen in “35%” of 
non-smokers as compared to “16%” of current smokers (p<0.05). The 
conclusion of the study was cigarette smoking was associated with lower 
short-term cardiac mortality in patients receiving thrombolysis for AMI. 
The “International Tissue Plasminogen Activator/Streptokinase 
Mortality Trial” showed A "smoker's paradox" and GISSI-2 trial showed only 
a non-significant trend for better outcome for smokers. These two studies 
bring forward the problem of the classification of former smokers.  
In the “GUSTO-1” study, 40,599 patients were included to analyse 30-
day mortality in relation to smoking. Smokers paradox was first coined in this 
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study. The "smoker's paradox" was predominantly observed in AMI patients 
selected according to the “WHO criteria” of the 1980s and 1990s during which 
time fibrinolysis was the dominant reperfusion strategy for AMI patients. 
INFLUENCE OF SYSTEMIC HYPERTENSION ON THROMBOLYSIS 
Hypertension is one of the leading causes of the global burden of 
disease. Nearly “13–15%” of the total deaths were attributable to high BP in 
2001. Hypertension doubles the risk of cardiovascular diseases, including 
coronary heart disease (CHD), congestive heart failure (CHF), ischemic and; 
hemorrhagic stroke, renal failure, and peripheral arterial disease. 
JNC 8 criteria: 
A person is said to be hypertensive and in need of medication if : 
i. In age > 60 years : BP > 150/90 mm of Hg  
ii. In age < 60 years : BP > 140/90 mm of Hg  
iii. In diabetics and CKD patients : Target BP should be  <140/90 mm 
of Hg  
Effect on thrombolysis: 
Though high BP is a major risk factor for CAD, hypertension per se has 
no major influence on the success or failure of thrombolysis. 
              A trial was conducted where a total of 373 patients (177 of whom had 
antecedent hypertension) were treated by thrombolysis because of STEMI. All 
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parameters were compared between the patients with and without 
hypertension. It was shown that hypertensive patients who received 
thrombolysis had higher rates of in-hospital mortality and major adverse 
cardiac events than patients without hypertension. 
A similar study “Original  research Factors  influencing  the  outcome  
of  thrombolysis  in  acute  myocardial infarction” was done by  
DrGirishRonad et al at,  Department  of  General  Medicine, ESIC  Medical  
College,  Gulbarga from  October  2011  to  October  2013. A total of 100 
patients were included in the study. The  success  rate  of  thrombolysis  was  
not found  to  be  different  among  hypertensive/non hypertensive patients . 
Among the 30 hypertensives, 21 were thrombolysed successfully and among 
the 70 non-hypertensives, 44 were thrombolysed successfull. p value was 0.47 
i.e. insignificant.  
INFLUENCE OF DIABETES ON THROMBOLYSIS: 
Diabetes mellitus (DM) refers to a group of common metabolic 
disorders that share the phenotype of hyperglycemia. The two broad categories 
of DM are designated type 1 and type 2 . “Type 1 DM”  results from complete 
or near-total insulin deficiency. “Type 2 DM” is a heterogeneous group of 
disorders characterized by variable degrees of insulin resistance, impaired 
insulin secretion, and increased glucose production. Type 2 DM is usually 
preceded by - impaired fasting glucose (IFG) or impaired glucose tolerance 
(IGT). 
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The worldwide prevalence of DM has risen dramatically from around 
“30 million” cases in 1985 to “285 million” in 2010. Based on current trends, 
the IDF projects that “438 million” individuals will have diabetes by the year 
2030 . DM increases with aging . India has the second largest population with 
diabetes. But it is estimated that at the current rate of progress, diabetics 
population in India will double in next 15 years and India will become the 
diabetic capital of the world by 2030.  
Criteria for the diagnosis of Diabetes Mellitus: 
i. Symptoms of diabetes plus RBS of >200 mg/dL or  
ii. FBS of >126 mg/dL or  
iii. A1C > 6.5% or  
iv. Two – hour PPBS  >200 mg/dL after an oral glucose tolerance test 
Chronic complications of Diabetes: 
x Microvascular complications:  
a) Retinopathy  
b) Neuropathy 
c) Nephropathy 
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x Macrovascular complications:  
a) Coronary artery disease  
b) Cerebrovascular disease 
c) Peripheral artery disease  
x Other systems  
a) Gastrointestinal 
b) Genitourinary 
c) Dermatologic 
d) Infectious 
e) Cataract and glaucoma 
f) Periodontal disease 
g) Hearing loss  
Effect on thrombolysis: 
                   “Type 2 diabetes” is a strong predictor of acute intravenous 
thrombolysis failure during STEMI. On receiving thrombolysis, the 
“diabetics” fare worse than the “non-diabetics”, manifesting as impaired post 
thrombolysis left ventricular function and poor prognosis. Diabetes causes 
accumulation of fatty acid intermediates which in turn promote ischemic 
injury through several mechanisms, 1 including direct toxicity, 2 increased 
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oxygen demand, 3 direct inhibition of glucose oxidation, and 4 subsequent 
production of free radicals which lead to loss of integrity of membrane and 
eventually cell death. 
A similar study “A comparative study on the effect of streptokinase 
between diabetic and non-diabetic myocardial infarction patients” was 
conducted by Md. Anup Rahman Chowdhury et al . Off the 187 study subjects 
with acute MI admitted at CCU, “126”patients were non-diabetic and” 61 
“patients were diabetic. Streptokinase was administered to all patients. 
Resolution (reduction) of “elevated ST segment  was evaluated after 90 
minutes of streptokinase administration. “Successful thrombolysis” (70% 
ST-resolution) was significantly higher in non-diabetic than diabetic 
(p<0.001), while “unsuccessful thrombolysis” (<30% ST resolution) was 
significantly higher in diabetic patients (p<0.001). It was concluded that 
diabetes mellitus might affect the thrombolytic outcome of acute MI in 
patients with diabetes mellitus. 
INFLUENCE OF WINDOW PERIOD ON THROMBOLYSIS: 
Fibrinolytic therapy can reduce the relative risk of in-hospital death by 
“up to 50%” when administered within the first hour of the onset of symptoms 
of STEMI, and much of this benefit is maintained for at least 10 years. The 
timing of reperfusion therapy by fibrinolysis or a catheter-based approach is 
important because myocardium can be saved only before it has been 
irreversibly injured . “Every minute is important” and those treated within 1–3 
h of the onset of symptoms generally benefit the most.  
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Some benefit is still possible even up to 12 h, especially if chest discomfort is 
still present and ST segments remain elevated.  
Door to needle time – it describes the time taken to administer the 
fibrinolytic agent after the patient has entered the ER door. The shorter the 
door to needle time, the more efficient ER is to cope with MI.  
         Door to balloon time – the interval between the arrival of the patient in 
the ER till the guidewire catheter crosses the occluded coronary artery in the 
cardiac cathlab. 
The success rate is higher if the patient presents earlier to hospital (< 3 
hours). The success rate declines as time progresses up to 12 hours after which 
time, fibrinolysis is rarely attempted.  
At  the GISSI trial,  the initial report changed the outlook of physicists 
all over  the world  regarding thrombolytic therapy for STEMI. Around 11,806 
patients from 176 coronary care units in different hospitals were included 
during a period of 17 months ( February 1984 to June 1985) for the study. The 
results showed patients had  higher chance of survival if the time was shorter 
between the symptom onset and the streptokinase infusion.  
INFLUENCE OF SITE OF THROMBUS IN CORONARY ARTERY ON 
THROMBOLYSIS: 
There are two coronary arteries, a left coronary and a right coronary. 
They arise from the left and right aortic sinuses respectively. Left main 
coronary artery divides into two main branches – LAD and LCX. The 
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dominating artery is the one which supplies the posterior inter ventricular 
septum. 
Inferior  wall  infarcts  have  higher  rate  of successful  thrombolysis  
compared  to  anterior  infarcts. The  reason  for  this  differential  response  
will  be evident  when  we  look  into  the  physiology  of coronary  circulation  
in  right  and  left  coronary arteries.  Blood  flow  in  right  coronary  artery  is 
relatively  independent  of  phases  of  cardiac  cycle, being  present  in  both  
systole  and  diastole.  Whereas flow  in  left  coronary  artery  is  almost  
absent  during systole  and  may  even  be  reversed  in  conditions  of 
heightened  micro  vascular  tone  and  left  ventricular hypertrophy. 
A Study “Predictors of inhospital outcome after acute inferior wall 
myocardial infarction”  was conducted by “Jim MH1, Chan AO, Tse HF, Lau 
CP et al”. From January 1997 to March 2006, around 546 patients  suffering 
from their first inferior wall myocardial infarction were included in the study. 
On comparing results with AWMI, IWMI is generally regarded as being low 
risk and had better rate of success in thrombolysis.  
Similar  observations  were  made  by C.Michael  Gibson,  Sabina  
Murphy  and  E. Brawnwald  et  al  (TIMI  study  group).  8  They  found that  
TIMI  grade  III  flow  rates  were  lower  for  left coronary  and  circumflex  
artery  compared  to  right coronary  artery  after  thrombolytic  therapy. 
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INFLUENCE OF KILLIP’S CLASSIFICATION ON THROMBOLYSIS 
 In 1967 Killip proposed a prognostic classification scheme based on 
whether the patient has rales on auscultation, in patients presenting with 
STEMI . The classification remains useful even today as seen from many MI 
trials. The classification is as follows: 
Class I :  “no rales” or a third heart sound. 
Class II: rales present but only to a “mild to moderate degree” (<50 percent of 
     lung fields) and may or may not have an S3 
Class III : rales in > 50% of each lung field and with “pulmonary edema.” 
Class IV : “cardiogenic shock” 
It has been found that Killip’s class greatly influences the thrombolysis 
outcome. 
A study “Original  research Factors  influencing  the  outcome  of  
thrombolysis  in  acute  myocardial infarction” was done by  DrGirishRonad et 
al at,  Department  of  General  Medicine, ESIC  Medical  College,  Gulbarga 
from  October  2011  to  October  2013. A total of 100 patients were included 
in the study. The  major  finding  of  this  study  is  that  the  time window  
period,  location  of  infarct  and haemodynamic  (Killips)  class  significantly  
affected the  outcome  of  thrombolysis.  For Killip classification , the p value 
was found to be < 0.05 ( statistical significance), with success rate highest for 
those who presented in KC I and failure rate highest for those who presented 
in KC IV. 
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MATERIALS AND METHODS 
 
PLACE OF STUDY: 
            The study was undertaken in IMCU , Department of General Medicine 
and Department of Cardiology, Chengalpattu medical college and hospital, 
Chengalpattu.  
DURATION OF STUDY :  1 year ( June 2014 – May 2015)  
POPULATION TO BE STUDIED : 100  
STUDY GROUP: 
20 TO 75 Yrs age group complaining of chest pain and ECG showing 
ST elevation (AWMI / IWMI) 
STUDY SETTING: 
IMCU, Dept of General Medicine, Chengalpattu Medical College and 
Hospital, Chengalpattu 
INCLUSION CRITERIA 
All patients with symptoms of Myocardial Infarction and showing ECG 
features of ACS STEMI – ST segment elevation in leads. 
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1.  ST segment elevation two consecutive ECG leads  
- Men > 40 yrs, “ST segment elevation “at the J point > 2mm in leads V2 
and V3, > 1 mm in all leads  
- Men < 40 yrs, “ST segment elevation” at the J point > 2.5 mm in leads 
V2 and V3  
- In women, “ST segment elevation” at the J point > 1.5mm in leads V2 
and V3, > 1 mm in all leads 
2.  New LBBB 
3.  Evidence of posterior MI 
- Threshold for abnormal St elevation at the J point is > 0.5 mm  
EXCLUSION CRITERIA: 
Adults not showing features of ACS – STEMI in ECG  
DATA COLLECTION: 
The participants were explained about the study and informed consent 
was obtained. Then they were interviewed and analysed for inclusion/ 
exclusion criteria. Cases which met the inclusion criteria and did not have any 
exclusion criteria were selected to participate in the study. 102 cases were 
included. 
x Detailed history regarding patient’s age, time of presentation to hospital 
from the onset of symptoms, lifestyle, history of smoking, history of 
drug intake for hypertension or diabetes were asked. Patients with low 
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physical activity and low commuting activity were taken as leading a 
sedentary lifestyle. Those who smoked > 5 cigarettes per day were 
considered as smokers. Symptom to needle time was taken for window 
period. Blood pressure was recorded and patients was auscultated for 
tabulating the patient as per Killip classification. 
INVESTIGATIONS DONE : 
 Blood pressure recording: Sphygmomanometer is used to record the 
blood pressure. BP is recorded in sitting posture in the right upper arm. Phase I 
Korotkoff sound was taken as systolic BP and disappearance of the sound 
(phase IV) was taken as diastolic BP.  
Electrocardiogram ( ECG ):  ECG changes of present myocardial 
infarction confirmed by echocardiography by an experienced cardiologist 
.ECG was taken to classify patients as having  AWMI or IWMI or LWMI or 
Triple vessel disease.  
Blood samples for RBS, FBS /PPBS:  
x Fasting blood glucose : done after 8 hours of fasting  
x Postprandial blood glucose : done 2 hours after taking food.  
Participant is diagnosed to be a diabetic if any one of the following is present: 
x FBS > 126 mg / dl  
x PPBS > 200 mg / dl 
x Patient already on anti – diabetic drugs  
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RESULTS AND ANALYSIS 
 
x 102 acute “ST elevation myocardial infarction” cases were included in 
the study. 
x Detailed history regarding patient’s age, time of presentation to hospital 
from the onset of symptoms, lifestyle, history of smoking, history of 
drug intake for hypertension or diabetes were asked.  
x Blood pressure was recorded and patients was auscultated for tabulating 
the patient as per Killip classification. 
x ECG was taken to classify them as AWMI or IWMI or LWMI or Triple 
vessel disease. 
x The various data were compared with successful / unsuccessful 
thrombolysis and their influence analysed. 
x The available data was subjected for statistical analysis. 
x The statistical comparison was done using “SPSS”.  
x The “p value of less than 0.05” was considered as statistically 
significant. 
x Charts and bar diagrams are shown to bring out the significance and 
understand them more easily. 
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TABLE 1: INFLUENCE OF AGE ON SUCCESS OF THROMBOLYSIS 
 
 
 
 
 
Success Failure 
Number Percentage within age 
Percentage 
within 
result 
Number Percentage within age 
Percentage 
within 
result 
< 40 yrs 12 66.7% 17.1% 6 33.3% 18.8% 
40 – 60 
yrs 43 76.8% 61.4% 13 23.2% 40.6% 
>60 yrs 15 53.6% 21.4% 13 46.4% 40.6% 
Pearson Chi – Square –  
Value – 2.786 
Df – 2 
 P = 0.248.  
Age has no significant relation with the success of thrombolysis. 
CHART 1 : SUCCESSFUL THROMBOLYSIS – AGEWISE 
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CHART 2: THROMBOLYSIS FAILURE – AGEWISE 
 
CHART 3 : AGEWISE DISTRIBUTION OF SUCCESSFUL AND 
UNSUCCESSFUL THROMBOLYSIS 
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TABLE 2 : INFLUENCE OF  SEX ON SUCCESS OF THROMBOLYSIS   
 
Success Failure 
Number 
Percentage 
within sex 
Percentage 
within 
result 
Number 
Percentage 
within sex 
Percentage 
within 
result 
Male 52 67.5% 74.3% 25 32.5% 78.1% 
Female 18 72% 25.7% 07 28% 21.9% 
Pearson Chi – Square –  
 Value – 0.175 
 Df – 1 
 P = 0.676 . 
 Fisher’s exact test = 0.439.  
Sex has no significant relation with the success of thrombolysis. 
CHART 4 : SUCCESSFUL THROMBOLYSIS – SEXWISE 
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CHART 5 : THROMBOLYSIS FAILURE – SEXWISE 
 
CHART 6 : SEXWISE DISTRIBUTION OF SUCCESSFUL AND 
UNSUCCESSFUL THROMBOLYSIS 
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TABLE 3 : INFLUENCE OF LIFESTYLE ON SUCCESS OF 
THROMBOLYSIS 
 
 
Success Failure 
Number 
Percentage 
within 
lifestyle 
Percentage 
within 
result 
Number 
Percentage 
within 
lifestyle 
Percentage 
within 
result 
Sedentary 29 61.7% 41.4% 18 38.3% 56.2% 
Active 41 74.5% 58.6% 14 25.5% 43.8% 
Pearson Chi – Square –  
 Value – 1.942 
 Df – 1 
 P = 0.163.  
 Fisher’s exact test = 0.119 . 
Lifestyle has no significant relation with the success of thrombolysis   
CHART 7 : SUCCESSFUL THROMBOLYSIS – LIFESTYLE WISE  
 
58 
 
CHART 8 : THROMBOLYSIS FAILURE – LIFESTYLE WISE  
 
CHART 9  : LIFESTYLE WISE DISTRIBUTION OF SUCCESSFUL 
AND UNSUCCESSFUL THROMBOLYSIS 
 
59 
 
TABLE 4 : INFLUENCE OF SMOKING ON SUCCESS OF 
THROMBOLYSIS 
 
 
Success Failure 
Number 
Percentage 
within 
smokers 
Percentage 
within 
results 
Number 
Percentage 
within 
smokers 
Percentage 
within 
results 
Smoker 32 72.7% 45.7% 12 27.3% 37.5% 
Non – 
smoker 
38 65.5% 54.3% 20 34.5% 62.5% 
 
Pearson Chi – Square –  
 Value – 0.604 
 Df – 1 
 P = 0.437 . 
 Fisher’s exact test – 0.288. 
Smoking has no significant relation with the success of thrombolysis . 
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CHART 10 :SMOKING INFLUENCE ON UNSUCCESSFUL 
THROMBOLYSIS 
 
CHART 11 : H/O SMOKING WISE  DISTRIBUTION OF 
SUCCESSFUL AND UNSUCCESSFUL THROMBOLYSIS 
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TABLE 5  : INFLUENCE OF SYSTEMIC HYPERTENSION ON 
SUCCESS OF THROMBOLYSIS  
 
Success Failure 
Number 
Percentage 
within 
SHT 
Percentage 
within 
result 
Number 
Percentage 
within 
SHT 
Percentage 
within 
result 
Systemic 
hypertension 
12 60% 17.1% 8 40% 25% 
Not a K/C/O 
Systemic 
hypertension 
58 70.7% 82.9% 24 
29.3% 
 
 
75% 
 
Pearson Chi – Square –  
 Value – 0.860 
 Df – 1 
 P = 0.354 
 Fisher’s exact test = 0.252 
Systemic Hypertension has no significant relation with the success of 
thrombolysis. 
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CHART 12 : SUCCESSFUL THROMBOLYSIS – H/O SHT 
 
 
CHART 13 : H/O SHT WISE  DISTRIBUTION OF SUCCESSFUL AND 
UNSUCCESSFUL THROMBOLYSIS 
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TABLE 6 : INFLUENCE OF DIABETES ON SUCCESS OF 
THROMBOLYSIS 
 
Success Failure 
Number 
Percentage 
within 
DM 
Percentage 
within 
result 
Number 
Percentage 
within 
DM 
Percentage 
within 
result 
H/O  
Diabetes 
18 60% 25.7% 12 40% 37.5% 
No H/O 
Diabetes 
52 72.2% 74.3% 20 27.8% 62.5% 
 
Pearson Chi – Square –  
 Value –1.469 
 Df – 1 
 P = 0.225 
 Fisher’s exact test = 0.164 
Diabetes  has no significant relation with the success of thrombolysis.   
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CHART 14  : SUCCESSFUL THROMBOLYSIS – H/O DIABETES 
 
CHART 15 :  H/O DIABETES WISE DISTRIBUTION OF 
SUCCESSFUL AND UNSUCCESSFUL THROMBOLYSIS 
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TABLE 7 : INFLUENCE OF WINDOW PERIOD ON SUCCESS OF 
THROMBOLYSIS 
 
Success Failure 
Number 
Percentage 
within 
window 
period 
Percentage 
within 
result 
Number 
Percentage 
within 
window 
period 
Percentage 
within 
result 
<3 
hrs 36 83.7% 51.4% 7 16.3% 21.9% 
3-6 
hrs 24 64.9% 34.3% 13 35.1% 40.6% 
>6hrs 10 45.5% 14.3% 12 54.5% 37.5% 
Pearson Chi – Square –  
 Value – 10.280 
 Df – 2 
 P <0.05. 
Window period from onset of pain to thrombolysis has significant 
relation with the success of thrombolysis.   
CHART 16 : SUCCESSFUL THROMBOLYSIS – INFLUENCE OF 
WINDOW PERIOD 
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CHART 17 : INFLUENCE OF WINDOW PERIOD - THROMBOLYSIS 
FAILURE 
 
CHART 18 : WINDOW PERIOD WISE DISTRIBUTION OF 
SUCCESSFUL AND UNSUCCESSFUL THROMBOLYSIS 
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TABLE 8 : INFLUENCE OF CORONARY ARTERY ANATOMY ON 
SUCCESS OF THROMBOLYSIS 
 Success 
 
Failure 
Number  Percentage 
within 
anatomy 
Percentage 
within 
result 
Number Percentage 
within 
anatomy 
Percentage 
within 
result 
AWMI Prox 
LAD 
21 53.8% 30% 18 46.2% 56.2% 
Between 
S1 & 
D1 
13 56.5% 18.6% 10 43.5% 31.2% 
IWMI Prox 
RCA  
25 92.6% 35.7% 2 7.4% 6.2% 
Distal 
RCA 
8 88.9% 11.4% 1 11.1% 3.1% 
LWMI – LCX 
territory 
2 100% 2.9% 0 0% 0% 
Triple vessel 
disease 
1 50% 1.4% 1 50% 3.1% 
Pearson Chi – Square –  
 Value – 15.678 
 Df – 5 
 P < 0.05 
Coronary artery anatomy has significant relation with the success of 
thrombolysis. 
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CHART 19 : THROMBOLYSIS FAILURE – ANATOMY WISE  
 
CHART 20 : ANATOMY WISE DISTRIBUTION OF SUCCESSFUL 
AND UNSUCCESSFUL THROMBOLYSIS 
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TABLE 9 : INFLUENCE OF KILLIP CLASSIFICATION ON SUCCESS 
OF THROMBOLYSIS 
 
 
 
Success Failure 
Number 
Percentage 
within KC 
Percentage 
within 
result 
Number 
Percentage 
within KC 
Percentage 
within 
result 
KC I 56 70.9% 80% 23 29.1% 71.9% 
KC 
II 
14 60.9% 20% 09 39.1% 28.1% 
 
Pearson Chi – Square –  
 Value – 0.830 
 Df – 1 
 P = 0.362 
 Fisher’s exact test = 0.253  
Killip classification  has no significant relation with the success of 
thrombolysis. 
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CHART 21 : THROMBOLYSIS FAILURE – KILLIP 
CLASSIFICATION WISE 
 
CHART 22 : KILLIP CLASSIFICATION WISE DISTRIBUTION OF 
SUCCESSFUL AND UNSUCCESSFUL THROMBOLYSIS 
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PART - B 
INFLUENCE OF FACTORS ON THROMBOLYSIS IN STEMI 
PRESENTING WITHIN 3 HOURS: 
TABLE 10 : INFLUENCE OF AGE ON SUCCESS OF 
THROMBOLYSIS: PRESENTATION < 3 HRS 
 
Success Failure 
Number 
Percentage 
within age 
Percentage 
within 
result 
Number 
Percentage 
within age 
Percentage 
within 
result 
< 40 
yrs 
9 81.8% 25% 2 18.2% 28.6% 
40 – 
60 yrs 
21 91.3% 58.3% 2 8.7% 28.6% 
>60 
yrs 
6 66.7% 16.7% 3 33.3% 42.8% 
Pearson Chi – Square : P = 0.232  
Age has no significant relation with the success of thrombolysis in 
cases presenting within window period of 3 hrs. 
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CHART 23 : AGEWISE DISTRIBUTION OF SUCCESSFUL 
AND UNSUCCESSFUL THROMBOLYSIS : WINDOW PERIOD < 3 
HRS 
 
TABLE 11 : INFLUENCE OF SEX ON SUCCESS OF 
THROMBOLYSIS : PRESENTATION < 3 HRS 
 
Success Failure 
Number Percentage within sex 
Percentage 
within 
result 
Number Percentage within sex 
Percentage 
within 
result 
Male 27 81.8% 75% 6 18.2% 85.7% 
Female 9 90% 25% 1 10% 14.3% 
Pearson Chi – Square : P = 0.476 .  
Sex has no significant relation with the success of thrombolysis in cases 
presenting within window period of 3 hrs. 
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CHART 24 : SEXWISE DISTRIBUTION OF SUCCESSFUL AND 
UNSUCCESSFUL THROMBOLYSIS : WINDOW PERIOD < 3 HRS 
 
TABLE 12 : INFLUENCE OF LIFESTYLE ON SUCCESS OF 
THROMBOLYSIS : PRESENTATION < 3 HRS 
 
Success Failure 
Number 
Percentage 
within 
lifestyle 
Percentage 
within 
result 
Number 
Percentage 
within 
lifestyle 
Percentage 
within 
result 
Sedentary 12 85.7% 33.3% 2 14.3% 28.6% 
Active 24 82.8% 66.7% 5 17.2% 71.4% 
Pearson Chi – Square: ( Fisher’s Exact test )  P = 0.590 .  
Lifestyle has no significant relation with the success of thrombolysis in 
cases presenting within window period of 3 hrs. 
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CHART 25 : LIFESTYLEWISE DISTRIBUTION OF SUCCESSFUL 
AND UNSUCCESSFUL THROMBOLYSIS : WINDOW PERIOD < 3 
HRS 
 
TABLE 13 : INFLUENCE OF SMOKING ON SUCCESS OF 
THROMBOLYSIS : PRESENTATION < 3 HRS 
 
Success Failure 
Number 
Percentage 
within 
smokers 
Percentage 
within 
results 
Number 
Percentage 
within 
smokers 
Percentage 
within 
results 
Smokers 14 93.3% 38.9% 1 6.7% 14.3% 
Non- 
smokers 22 78.6% 61.1% 6 21.4% 85.7% 
Pearson Chi – Square : ( Fisher’s Exact test )  P = 0.212 .  
Smoking has no significant relation with the success of thrombolysis in 
cases presenting within window period of 3 hrs. 
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CHART 26 : INFLUENCE OF SMOKING ON DISTRIBUTION OF 
SUCCESSFUL AND UNSUCCESSFUL THROMBOLYSIS : WINDOW 
PERIOD < 3 HRS 
 
TABLE 14 : INFLUENCE OF SYSTEMIC HYPERTENSION ON 
SUCCESS OF THROMBOLYSIS : PRESENTATION < 3 HRS 
 
Success Failure 
Number 
Percentage 
within 
SHT 
Percentage 
within 
result 
Number 
Percentage 
within 
SHT 
Percentage 
within 
result 
SHT 5 71.4% 13.9% 2 28.6% 28.6% 
No – 
SHT 31 86.1% 86.1% 5 13.9% 71.4% 
Pearson Chi – Square (Fisher’s exact test) : P = 0.318.  
Systemic hypertension has no significant relation with the success of 
thrombolysis in cases presenting within window period of 3 hrs. 
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CHART 27 : INFLUENCE OF SHT ON DISTRIBUTION OF 
SUCCESSFUL AND UNSUCCESSFUL THROMBOLYSIS : WINDOW 
PERIOD < 3 HRS 
 
 
 
 
 
 
TABLE 15 : INFLUENCE OF DIABETES ON SUCCESS OF 
THROMBOLYSIS : PRESENTATION < 3 HRS 
 
Success Failure 
Number 
Percentage 
within 
diabetes 
Percentage 
within 
result 
Number 
Percentage 
within 
diabetes 
Percentage 
within 
result 
Diabetic 8 66.7% 22.2% 4 33.3% 57.1% 
Non-
diabetic 28 90.3% 77.8% 3 9.7% 42.9% 
Pearson Chi – Square (Fisher’s exact test)  : P = 0.081.  
Diabetes has comparatively some significant relation with the success 
of thrombolysis in cases presenting within window period of 3 hrs. 
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CHART 28 : INFLUENCE OF H/O DIABETES ON DISTRIBUTION 
OF SUCCESSFUL AND UNSUCCESSFUL THROMBOLYSIS: 
WINDOW PERIOD < 3 HRS 
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TABLE 16 : INFLUENCE OF CORONARY ARTERY ANATOMY ON 
SUCCESS OF THROMBOLYSIS : PRESENTATION < 3 HRS 
 
 
Success Failure 
Number 
Percentage 
within 
anatomy 
Percentage 
within 
result 
Number 
Percentage 
within 
anatomy 
Percentage 
within 
result 
LAD 
Prox 
LAD 10 76.9% 27.8% 3 23.1% 42.9% 
Between 
S1 & 
D1 
6 60% 16.7% 4 40% 57.1% 
RCA 
Prox 
RCA 12 100% 33.3% 0 0% 0% 
Distal 
RCA 6 100% 16.7% 0 0% 0% 
LCX 1 100% 2.8% 0 0% 0% 
TVD 1 100% 2.8% 0 0% 0% 
 
Pearson Chi – Square : P = 0.051.  
Coronary artery anatomy has significant relation with the success of 
thrombolysis in cases presenting within window period of 3 hrs. 
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CHART 29 : ANATOMY - WISE DISTRIBUTION OF 
SUCCESSFUL AND UNSUCCESSFUL THROMBOLYSIS : WINDOW 
PERIOD < 3 HRS 
 
TABLE 17 : INFLUENCE OF KILLIP CLASSIFICATION ON 
SUCCESS OF THROMBOLYSIS : PRESENTATION < 3 HRS 
 
Success Failure 
Number Percentage within KC 
Percentage 
within 
result 
Number Percentage within KC 
Percentage 
within 
result 
KC 
I 29 80.6% 80.6% 7 
19.4% 
 
 
100% 
KC 
II 7 100% 19.4% 0 0% 0% 
Pearson Chi – Square ( Fisher’s exact test ) : P = 0.259 .  
Killip classification has no significant relation with the success of 
thrombolysis in cases presenting within window period of 3 hrs. 
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CHART 30 : KILLIP CLASSIFICATION-WISE DISTRIBUTION OF 
SUCCESSFUL AND UNSUCCESSFUL THROMBOLYSIS : WINDOW 
PERIOD < 3 HRS 
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PART - C 
OTHER IMPORTANT FINDINGS OF SIGNIFICANCE IN THE 
STUDY: 
TABLE 18 : INFLUENCE OF SEX ON SUCCESS OF 
THROMBOLYSIS : PRESENTATION >6 HRS 
 
Success Failure 
Number Percentage within sex 
Percentage 
within 
result 
Number Percentage within sex 
Percentage 
within 
result 
Male 4 28.6% 40% 10 71.4% 83.3% 
Female 6 75% 60% 2 25% 16.7% 
Pearson Chi – Square ( Fisher’s exact test ) : P < 0.05.  
Sex has significant relation with the success of thrombolysis in cases 
presenting within window period of > 6 hrs . 
CHART 31 :  SEXWISE DISTRIBUTION OF SUCCESSFUL AND 
UNSUCCESSFUL THROMBOLYSIS : WINDOW PERIOD >6 HRS 
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TABLE 19 : INFLUENCE OF CORONARY ARTERY ANATOMY ON 
SUCCESS OF THROMBOLYSIS : PRESENTATION >6 HRS  
 
Success Failure 
Number 
Percentage 
within 
anatomy 
Percentage 
within 
result 
Number 
Percentage 
within 
anatomy 
Percentage 
within 
result 
LAD 
Prox 
LAD 2 25% 20% 6 75% 50% 
Between 
S1 & 
D1 
1 20% 10% 4 80% 33.3% 
RCA 
Prox 
RCA 6 85.7% 60% 1 14.3% 8.3% 
Distal 
RCA 1 100% 10% 0 0% 0% 
LCX 0 0% 0% 0 0% 0% 
TVD 0 0% 0% 1 100% 8.3% 
 
Pearson Chi – Square : P = 0.05.  
Coronary artery anatomy has significant relation with the success of 
thrombolysis in cases presenting within window period of  >6 hrs.  
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CHART 32: ANATOMYWISE DISTRIBUTION OF SUCCESSFUL 
AND UNSUCCESSFUL THROMBOLYSIS : WINDOW PERIOD >6 
HRS 
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DISCUSSION 
 
                On analyzing the data of 102 patients thrombolysed in the time 
period of one year (June 2014 – May 2015) in intensive care unit of 
Chengalpattu government college and hospital, it was found that 70 patients 
(68.6%) were successfully thrombolysed while 32 patients (31.4%) had a 
failure in thrombolysis using Inj. Streptokinase as thrombolysing agent. The 
influence of various factors on thrombolysis were analysed. 
A similar study on “factors affecting thrombolysis in myocardial 
infarction myocardial perfusion frame count: insights of myocardial tissue-
level reperfusion from a novel index for assessing myocardial perfusion” was 
conducted by Pu J, Shan PR and co. A total of 255 consecutive STEMI 
patients undergoing thrombolysis were enrolled. 1 Advanced age, 2 diabetes, 3 
higher Killip class, and 4 longer ischemia time were independent predictors of 
impaired TMPFC after thrombolysis. 
A similar study “Original  research Factors  influencing  the  outcome  
of  thrombolysis  in  acute  myocardial infarction” was done by  
DrGirishRonad et al at,  Department  of  General  Medicine, ESIC  Medical  
College,  Gulbarga from  October  2011  to  October  2013. A total of 100 
patients were included in the study. All  patients  were  evaluated  in  detail  
and  followed  until  discharge  from  the  hospital. Results were that the 
overall  success  rate  of  thrombolysis  was  65%.   Time  window  period,  
that  is  those  presenting  within  0-4  hrs  of symptom  onset  had  higher  
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success  rate  compared  to  those  presenting  later  (P<0.01).  Location  of  
MI  that  is  those  with  inferior wall  infarctions  had  higher  success  rate  
compared  to  anterior  wall (P<0.05).  Patients presenting with  higher  Killips  
had  high failure  rate  (P<0.05).  Diabetics,  hypertensives,  smokers  and  
alcoholics  did  not  differ  statistically  compared  to  non  diabetics,  non 
hypertensives,  non  smokers  and  non  alcoholics respectively  with  P>0.05.  
Streptokinase/ tenecteplase  did  not  differ  in  their outcome  statistically  
(P>0.05). 
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PART - A 
Influence of age on thrombolysis : 
             In our study, of the 102 patients thrombolysed, 18 were < 40 yrs of 
age, 56 were in the age group between 40 to 60 years and 28 were > 60 years 
of age. The success rate of thrombolysis in the age group <40 years, 40 – 60 
years and > 60 years were found to be 66.7% , 76.8% and 53.6% respectively 
and the failure rate among those thrombolysed in the age group < 40 years, 40 
– 60 years and > 60 years were found to be 33.3%, 23.2 % and 46.4% 
respectively. Success rate was found to be comparatively better for those aged 
< 60 years. But on statistical analysis, there was no significant relationship 
between age distribution and result of thrombolysis using Inj. Streptokinase.  
(p = 0.248 ) . 
A Study on “ Acute Coronary Syndrome In Elderly – The Difference,  
Compared With Young In Intensive Care Unit Of A Tertiary Hospital “In 
Western Nepal was done on patients admitted to ICU in the “Manipal 
Teaching Hospital “in the month of “March 2006 to June 2007”. Out of 153 
patients were analyzed - elderly patients (> 65 yrs) constituted 51% (78) of the 
study population. The success rate of thrombolysis was lower in elderly 
patients (50%) as compared to young patients (76.9%). The end result of the 
study was elderly patients are more prone to complications have less success 
rate for thrombolysis and have a higher mortality rate when compared to 
young patients. 
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Influence of sex on thrombolysis : 
In our study, of the 102 patients thrombolysed, 77 were male and 25 were 
female. The success rate of thrombolysis among males and females were 
found to be 67.5% and 72% respectively and the failure rate of thrombolysis 
among males and females were found to be 32.5% and 28% respectively. 
Hence there was no much difference on the success and failure rates among 
males and females. No significant statistical relationship could be found on the 
influence of sex on thrombolysis using Inj. Streptokinase (p = 0.676).  
               A study  “Gender and acute myocardial infarction: is there a different 
response to thrombolysis?” was conducted by Woodfield SL1, Lundergan CF 
and co. Patency rates and global and regional left ventricular function were 
determined in patients at “90 min” and “5 to 7 days” after thrombolytic 
therapy for acuteMI. The results “ninety-minute post thrombolysis” in women 
and men were 39% and 38%, respectively (p = 0.5). Women had more 
recurrent ischemia than men. The conclusion of the study was women do not 
differ significantly from men with regard to early infarct-related artery patency 
rates. Gender was a factor independent of the success and failure rate of 
thrombolysis. 
Influence of lifestyle on thrombolysis : 
In our study, of the 102 patients thrombolysed, 47 were leading a 
sedentary lifestyle and 55 were active or leading a non-sedentary lifestyle. The 
success and failure rate of thrombolysis among those with sedentary lifestyle 
were found to be 61.7% and 38.3% respectively and the success and failure 
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rate of thrombolysis among those with non-sedentary or active lifestyle were 
found to be 74.5% and 25.5% respectively. Hence success rate was to be 
comparatively higher among those with a non-sedentary lifestyle or an active 
lifestyle when compared to a sedentary lifestyle. However on statistical 
analysis, there was no significant relationship between lifestyle of the patients 
and result of thrombolysis using Inj. Streptokinase (p = 0.163).  
Influence of smoking on thrombolysis (Smoking paradox ?):  
In our study, of the 102 patients thrombolysed, 44 were smokers and 58 
were non-smokers.  The success and failure rate of thrombolysis among 
smokers were found to be 72.7% and 27.3% respectively and the success and 
failure rate of thrombolysis among non-smokers were found to be 65.5% and 
34.5% respectively. Among the failure cases, 62.5% were non-smokers and 
37.5% were smokers. Hence smokers had a slightly higher success rate of 
thrombolysis when compared to the non-smokers. But on statistical analysis 
,there was no significant relationship between history of smoking among the 
patients and result of thrombolysis using Inj. Streptokinase ( p = 0.288).  
A study “Lower cardiac mortality in smokers following thrombolysis 
for acute myocardial infarction may be related to more effective fibrinolysis”. 
Of the 332 patients with AMI, 48% were current smokers, 19% previous 
smokers and 33% had never smoked. Results were a successful thrombolysis 
(by 60 mins ) was achieved by “44%” of current smokers compared with  43% 
of non-smokers. Unsuccessful thrombolysis (by 180 min ) was seen in “35%” 
of non-smokers as compared to “16%” of current smokers (p<0.05). The 
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conclusion of the study was cigarette smoking was associated with lower 
short-term cardiac mortality in patients receiving thrombolysis for AMI. 
But insignificant.”CindyL. Gines, E.J. Topolet al.14” reported similar 
patency rates in smokers and nonsmokers at 90 minutes (73% versus 74%). 
          The term "smoker's paradox" was introduced into scientific discourse 
more than 25 years ago following observations that smokers (in comparison to 
non-smokers) experience decreased mortality following an acute myocardial 
infarction (AMI). In recent studies, it is shown that “ Smokers paradox” is not 
seen in those undergoing PCI.  
The “International Tissue Plasminogen Activator/Streptokinase 
Mortality Trial” shows  "smoker's paradox" and GISSI-2 trial showed only a 
non-significant trend for better outcome for smokers. These two studies bring 
forward the problem of the classification of former smokers.  
In the “GUSTO-1” study, 40,599 patients were included to analyse 30-
day mortality in relation to smoking. Smokers paradox was first coined in this 
study. The "smoker's paradox" was predominantly observed in AMI patients 
selected according to the “WHO criteria” of the 1980s and 1990s during which 
time fibrinolysis was the dominant reperfusion strategy for AMI patients. 
Influence of systemic hypertension on thrombolysis : 
In our study, of the 102 patients thrombolysed, 20 were hypertensives 
on medications and 82 were non-hypertensives. The success and failure rate of 
thrombolysis among hypertensives were found to be 60% and 40% 
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respectively and the success and failure rate of thrombolysis among non-
hypertensives were found to be 70.7% and 29.3% respectively. On statistical 
analysis, there was no significant relationship between hypertension and result 
of thrombolysis using Inj.Streptokinase (p = 0.354)  
 A similar study “Original  research Factors  influencing  the  outcome  
of  thrombolysis  in  acute  myocardial infarction” was done by  
DrGirishRonad et al at,  Department  of  General  Medicine, ESIC  Medical  
College,  Gulbarga from  October  2011  to  October  2013. A total of 100 
patients were included in the study. The  success  rate  of  thrombolysis  was  
not found  to  be  different  among  hypertensive/non hypertensive patients . 
Among the 30 hypertensives, 21 were thrombolysed successfully and among 
the 70 non-hypertensives, 44 were thrombolysed successfully. p value was 
0.47 i.e. insignificant.  
A trial was conducted where a total of (373 patients (177 of whom had 
antecedent hypertension) were treated by thrombolysis because of STEMI. All 
parameters were compared between the patients with and without 
hypertension. It was shown that hypertensive patients who received 
thrombolysis had higher rates of in-hospital mortality and major adverse 
cardiac events than patients without hypertension. 
Influence of diabetes on thrombolysis: 
In our study, of the 102 patients thrombolysed, 30 were diabetic and 72 
were non-diabetic. The success and failure rate of thrombolysis among 
diabetics were found to be 60% and 40% respectively and the success and 
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failure rate of thrombolysis among non-diabetics were found to be 72.2% and 
27.8% respectively. On statistical analysis, there was no significant 
relationship between diabetes and result of thrombolysis using 
Inj.Streptokinase ( p = 0.225 )  
But at a similar study “Original  research Factors  influencing  the  
outcome  of  thrombolysis  in  acute  myocardial infarction “was done by  
DrGirishRonad et al at,  Department  of  General  Medicine, ESIC  Medical  
College,  Gulbarga from  October  2011  to  October  2013 where a total of 
100 patients were included in the study, the  success  rate  of  thrombolysis  
was  not found  to  be  different  among  diabetic and non-diabetic patients      
(p = 0.38 ).  
A similar study “A comparative study on the effect of streptokinase 
between diabetic and non-diabetic myocardial infarction patients” was 
conducted by Md. Anup Rahman Chowdhury et al . Off the 187 study subjects 
with acute MI admitted at CCU, “126” patients were non-diabetic and” 61 
“patients were diabetic. Streptokinase was administered to all patients. 
Resolution (reduction) of “elevated ST segment was evaluated after 90 
minutes of streptokinase administration. “Successful thrombolysis” (70% 
ST-resolution) was significantly higher in non-diabetic than diabetic 
(p<0.001), while “unsuccessful thrombolysis” (<30% ST resolution) was 
significantly higher in diabetic patients (p<0.001). It was concluded that 
diabetes mellitus might affect the thrombolytic outcome of acute MI in 
patients with diabetes mellitus. 
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Influence of window period on thrombolysis: 
In our study, of the 102 patients thrombolysed, 43 patients were 
thrombolysed within 3 hours, 37 patients between 3 to 6 hours and 22 patients 
in more than 6 hours (till 12 hours). The success and failure rate of 
thrombolysis within 3 hours were found to be 83.7% and 16.3% respectively, 
the success and failure rate of thrombolysis between 3 to 6 hours were found 
to be 64.9% and 39.1% respectively and the success and failure rate of 
thrombolysis in more than 6 hours (< 12 hours) were found to be 45.5% and 
54.5% respectively. On statistical analysis, there was significant relationship 
between window period and result of thrombolysis using Inj.Streptokinase    
(p < 0.05) . Success rate of thrombolysis is found to be greater for the patients 
thombolysed within 3 hours (83.7%), decreased to 64.9%  in those between 3 
to 6 hours and further decreased to 45.5% in those thrombolysed in more than 
6 hours. 
At the GISSI trial,  the initial report changed the outlook of physicists 
all over  the world  regarding thrombolytic therapy for STEMI. Around 11,806 
patients from 176 coronary care units in different hospitals were included 
during a period of 17 months (February 1984 to June 1985) for the study. The 
results showed patients had higher chance of survival if the time was shorter 
between the symptom onset and the streptokinase infusion.  
A similar study “Original  research Factors  influencing  the  outcome  
of  thrombolysis  in  acute  myocardial infarction “was done by  
DrGirishRonad et al at,  Department  of  General  Medicine, ESIC  Medical  
College,  Gulbarga from  October  2011  to  October  2013. A total of 100 
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patients were included in the study. In this  study  also  it  is  evident.  Success  
rate  was  80% in  those  patients  thrombolysed  within  4  hours  from the  
onset  of  symptoms.  The  success  rate  decreased  to 61.7%,  when  they  
were  thrombolysed  after  4  hrs  but within  8  hours  of  onset  of  symptoms.  
Success  rate came  down  to  30.7%,  when  STK/  TNK  was administered  
after  8  hours  but  within  12  hours ( p < 0.01). 
Influence of localization of thrombus in coronary artery on thrombolysis: 
In our study , of the 102 patients thrombolysed, 39 had occlusion at 
proximal LAD, 23 in between D1 and S1 branches of LAD, 27 in proximal 
RCA, 9 in distal RCA, 2 in LCX and 2 patients had triple vessel disease. The 
success and failure rate of thrombolysis in those who had occlusion in 
proximal LAD were found to be 53.8% and 46.2% respectively, between D1 
and S1 branches of LAD were found to be 56.5% and 43.5% respectively , in 
proximal RCA  92.6% and 7.4% respectively, in distal RCA 88.9% and 11.1% 
respectively and in LCX 100% and 0% respectively and in triple vessel 
disease were found to be 50% and 50% respectively. The success rate was 
found to be higher for those who had occlusion in Right coronary artery than 
in any other vessel. On statistical analysis, there was significant relationship 
between localization of occlusion in coronary artery and result of thrombolysis 
using Inj.Streptokinase ( p  < 0.05 ) .  
                A Study “Predictors of inhospital outcome after acute inferior wall 
myocardial infarction”  was conducted by “Jim MH1, Chan AO, Tse HF, Lau 
CP et al”. From January 1997 to March 2006, around 546 patients suffering 
from their first inferior wall myocardial infarction were included in the study. 
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On comparing results with AWMI, IWMI is generally regarded as being low 
risk and had better rate of success in thrombolysis .  
A similar study “Original  research Factors  influencing  the  outcome  
of  thrombolysis  in  acute  myocardial infarction “was done by  
DrGirishRonad et al at ,  Department  of  General  Medicine, ESIC  Medical  
College,  Gulbarga from  October  2011  to  October  2013. A total of 100 
patients were included in the study. Location  of  Infarct  and  Outcome In  our  
study,  inferior  wall  infarcts  had  higher  rate  of successful  thrombolysis  
compared  to  anterior  infarcts and  the  difference  was  statistically  
significant (P<0.05).   
Similar  observations  were  made  by  “C.Michael  Gibson,  Sabina  
Murphy  and  E. Brawnwald  et  al  (TIMI  study  group)”.  They  found that  
TIMI  grade  III  flow  rates  were  lower  for  left coronary  and  circumflex  
artery  compared  to  right coronary  artery  after  thrombolytic  therapy. 
Influence of Killip classification at the time of presentation on 
thrombolysis : 
In our study, of the 102 patients thrombolysed, 79 patients presented in 
KC I and 23 in KC II . The success and failure rate of thrombolysis in those 
who presented with KC I were found to be 70.9% and 29.1% respectively and 
the success and failure rate of thrombolysis in those who presented with KC II 
were found to be 60.9% and 39.1% respectively. No patients presented in 
KCIII and KC IV presentations. On statistical analysis, there was no 
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significant relationship between Killip classification at the time of presentation 
and result of thrombolysis using Inj.Streptokinase (p = 0.362).  
A similar study “Original  research Factors  influencing  the  outcome  
of  thrombolysis  in  acute  myocardial infarction “was done by  
DrGirishRonad et al at,  Department  of  General  Medicine, ESIC  Medical  
College,  Gulbarga from  October  2011  to  October  2013. A total of 100 
patients were included in the study. The  major  finding  of  this  study  is  that  
the  time window  period,  location  of  infarct  and haemodynamic  (killips)  
class  significantly  affected the  outcome  of  thrombolysis. For Killip 
classification, the p value was found to be < 0.05 ( statistical significance ), 
with success rate highest for those who presented in KC I and failure rate 
highest for those who presented in KC IV.   
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PART - B  
Influence of age on thrombolysis ( presentation< 3 hours ) : 
In our study, of the 43 patients thrombolysed who presented within 3 
hours of the onset of chest pain , 11 were < 40 years of age, 23 were between 
40 to 60 years of age and 9 were > 60 years of age. The success and failure 
rate of thrombolysis in those who presented within 3 hours and those who 
were < 40 years of age were found to be 81.8% and 18.2% respectively, those 
between 40 to 60 years were found to be 91.3% and 8.7% respectively and, 
those who presented with age > 60 years were found to be 66.7% and 33.3% 
respectively. The success rate was found to be higher for those with age less 
than 60 years than with age more than 60 years. On statistical analysis, there 
was no significant relationship between age and result of thrombolysis using 
Inj.Streptokinase in those who presented in less than 3 hours ( p = 0.232 ). 
Influence of sex on thrombolysis( presentation< 3 hours ) : 
In our study, of the 43 patients thrombolysed who presented within 3 
hours of the onset of chest pain, 33 were male and 10 were female. The 
success rate of thrombolysis in males and females and those who presented 
within 3 hours were found to be 81.8% and 90% respectively and failure rate 
of thrombolysis in males and females and those who presented within 3 hours 
were found to be 18.2% and 10% respectively. On statistical analysis, there 
was no significant relationship between sex and result of thrombolysis using 
Inj.Streptokinase in those who presented in less than 3 hours (p = 0.476)  
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Influence of lifestyle on thrombolysis( presentation< 3 hours ): 
In our study, of the 43 patients thrombolysed who presented within 3 
hours of the onset of chest pain, 14 were leading a sedentary lifestyle and 29 
were active or leading a non-sedentary lifestyle. The success rate of 
thrombolysis in those leading a sedentary and non-sedentary lifestyle and 
those who presented within 3 hours were found to be 85.7% and 82.2% 
respectively and the failure rate of thrombolysis in those leading a sedentary 
and non-sedentary lifestyle and those who presented within 3 hours were 
found to be 14.3% and 17.2% respectively. On statistical analysis ,there was 
no significant relationship between lifestyle and result of thrombolysis using 
Inj.Streptokinase in those who presented in less than 3 hours (p = 0.590). 
Influence of smoking on thrombolysis( presentation< 3 hours ): 
In our study, of the 43 patients thrombolysed who presented within 3 
hours of the onset of chest pain, 15 were smokers and 28 were non-smokers. 
The success rate of thrombolysis in smokers and non-smokers and those who 
presented within 3 hours were found to be 98.3% and 78.6% and failure rate of 
thrombolysis in smokers and non-smokers and those who presented within 3 
hours were found to be 6.7% and 21.4% respectively. The success rate was 
found to be a bit higher in smokers than in non-smokers .On statistical analysis 
,there was no significant relationship between smoking and result of 
thrombolysis using Inj.Streptokinase in those who presented in less than 3 
hours (p = 0.212 )   
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Influence of systemic hypertension on thrombolysis( presentation< 3 
hours): 
In our study, of the 43 patients thrombolysed who presented within 3 
hours of the onset of chest pain, 7 were hypertensives and on medications and 
36 were non-hypertensives. The success rate of thrombolysis in hypertensives 
and non-hypertensives and those who presented within 3 hours were found to 
be 71.4% and 86.1% respectively and failure rate of thrombolysis in 
hypertensives and non-hypertensives and those who presented within 3 hours 
were found to be 28.6% and 13.9% respectively. On statistical analysis, there 
was no significant relationship between systemic hypertension and result of 
thrombolysis using Inj.Streptokinase in those who presented in less than 3 
hours ( p = 0.318 ).  
Influence of diabetes on thrombolysis( presentation< 3 hours ): 
In our study, of the 43 patients thrombolysed who presented within 3 
hours of the onset of chest pain, 12 were diabetic and 31 were non-diabetics. 
The success rate of thrombolysis in diabetics and non-diabetics and those who 
presented within 3 hours were found to be 66.7% and 90.3% respectively and 
failure rate of thrombolysis in diabetics and non-diabetics and those who 
presented within 3 hours were found to be 33.3% and 9.7% respectively. The 
success rate was found to be a higher in non-diabetics than in diabetics .On 
statistical analysis ,there was no significant relationship between diabetes and 
result of thrombolysis using Inj.Streptokinase in those who presented in less 
than 3 hours (p = 0.081).  
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Influence of localization of thrombus in coronary artery on thrombolysis 
(presentation< 3 hours): 
In our study, of the 43 patients thrombolysed who presented within 3 
hours of the onset of chest pain, 13 had thrombus in proximal LAD, 10 in 
between S1 and D1 branches of LAD, 12 in proximal RCA, 6 in distal RCA, 1 
in LCX and 1 had Triple vessel disease. The success rate and failure rate of 
thrombolysis in those who had occlusion in proximal LAD and those who 
presented within 3 hours were found to be 76.9% and 23.1% respectively, in 
those who had occlusion in between S1 and D1 branches of LAD were found 
to be 60% and 40% respectively, in those who had occlusion in proximal RCA 
were found to be 100% and 0% respectively and in those who had occlusion in 
distal RCA were found to be 100% and 0% respectively. The success rate was 
found to be a higher in those who had thrombus occlusion in right coronary 
artery and presented as inferior wall myocardial infarction than in those who 
presented as anterior wall myocardial infarction with LAD lesion. On 
statistical analysis, there was significant relationship between localization of 
thrombus in coronary artery and result of thrombolysis using Inj.Streptokinase 
in those who presented in less than 3 hours (p = 0.05 ).  
Influence of Killip classification at the time of presentation on 
thrombolysis( presentation< 3 hours ) : 
In our study, of the 43 patients thrombolysed who presented within 3 
hours of the onset of chest pain, 36 presented in KC I and 7 presented in KC 
II. The success rate of thrombolysis in KC I and KCII and those who 
presented within 3 hours were found to be 80.6% and 100% respectively and 
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failure rate of thrombolysis in KC I and KCII and those who presented within 
3 hours were found to be 19.4% and 0% respectively. On statistical analysis, 
there was no significant relationship between Killip classification and result of 
thrombolysis using Inj.Streptokinase in those who presented in less than 3 
hours (p = 0.259).  
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PART - C  
Other important findings from the study: 
Influence of sex on thrombolysis( presentation> 6 hours ) : 
In our study, of the 22 patients thrombolysed who presented more than 
6 hours of the onset of chest pain (< 12 hours ), 14 were male and 8 were 
female . The success rate of thrombolysis in male and female and those who 
presented more than 6 hours after the onset of symptoms (< 12 hours ) were 
found to be 28.6% and 75% respectively and failure rate of thrombolysis in 
male and female and those who presented more than 6 hours after the onset of 
symptoms (< 12 hours) were found to be 71.4% and 25% respectively. The 
success rate was found to be higher in females than in males in those who 
presented more than 6 hours of the onset of symptoms. On statistical analysis, 
there was significant relationship between sex and result of thrombolysis using 
Inj.Streptokinase in those who presented more than 6 hours of the onset of 
symptoms (p < 0.05).  
Influence of localization of thrombus in coronary artery on thrombolysis 
(presentation> 6 hours ): 
In our study, of the 22 patients thrombolysed who presented more than 
6 hours of the onset of chest pain (< 12 hours), 8 had thrombus in proximal 
LAD, 5 in between S1 and D1 branches of LAD, 7 in proximal RCA, 1 in 
distal RCA and 1 had Triple vessel disease. The success rate and failure rate of 
thrombolysis in those who had occlusion in proximal LAD and those who 
presented more than 6 hours were found to be 25% and 75% respectively, in 
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those who had occlusion in between S1 and D1 branches of LAD were found 
to be 20% and 80% respectively, in those who had occlusion in proximal RCA 
were found to be 85.7% and 14.3% respectively and in those who had 
occlusion in distal RCA were found to be 100% and 0% respectively. The 
success rate was found to be a higher in those who had thrombus occlusion in 
right coronary artery and presented as inferior wall myocardial infarction than 
in those who presented as anterior wall myocardial infarction with LAD lesion 
.On statistical analysis, there was significant relationship between localization 
of thrombus in coronary artery and result of thrombolysis using 
Inj.Streptokinase in those who presented more than 6 hours of the onset of 
symptoms ( P = 0.05 ) . 
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CONCLUSION 
 
1. Inferior  wall  myocardial  infarctions  had  a better  success  rate  than  
anterior  wall myocardial  infarctions  and  it  was statistically  
significant. But there was no significant difference on the influence of 
site within the RCA or the LAD on the success of thrombolysis. 
2. Time  window  period  significantly influenced  the  outcome  of  
thrombolysis, implying that  earlier  the  presentation  ,  better  is the  
success  rate. Success rate was higher in those who presented in less 
than 3 hours. 
3. Smokers  had  a  higher  success  rate  than  non smokers,  but  it  did  
not  reach  statistical significance. 
4. Age-wise success rate was found to be higher in those less than 60 
years of age than those of more than 60 years. But it  was not  
statistically  significant.    
5. Gender was  not  found  to  influence  the success rate of thrombolysis. 
But in presentation >6 hours,  who underwent thrombolysis with 
Inj.Streptokinase, success rate was found to be higher in females than in 
males with statistical significance .  
6. Lifestyle was not found to influence the result of thrombolysis. 
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7. Presence or absence of systemic hypertension at the time of 
presentation for thrombolysis had no influence on the success or failure. 
8. Diabetics  do  not  differ  from  non  diabetics with  respect  to  the  
success  rate  of thrombolysis. But in those who presented in less than 3 
hours with symptoms , the success rate was higher in non-diabetics than 
in diabetics , though it was statistically insignificant.  
9. Killip classification at the time of presentation was not found to 
influence the success rate of thrombolysis. 
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LIMITATIONS OF THE STUDY: 
 
1. Smaller sample size. 
2. Cross sectional study design. 
3. Chances of confounding bias are more. 
4. No coronary angiogram to confirm the localization of thrombus in the 
coronary arteries, which is based on ECG  features alone in this study.  
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Sl 
no 
Name Age Sex Window Lifestyle Smoking Diabetes Sht Type Anatomy Killip 
class 
Result 
1 Gnanam 40 m 4 hrs NS no no no AWMI prox LAD KC I failure 
2 Lakshmi 60 f 5 hrs S no no no AWMI prox LAD KC I  success 
3 Neelagandan 50 m 6 hrs S 20 yrs  no no IWMI prox RCA KC I success 
4 
Murali 40 m 7 hrs S 20 yrs  no no AWMI 
prox to D1 
, distal t S1  KC II failure 
5 
Sekar 47 m 5 hrs  NS  15 yrs no no AWMI 
prox to D1 
, distal t S1  KC I  
partially 
success 
6 Noorallah 51 m 3 hrs  NS no no no AWMI prox LAD KC II success 
7 
Paramasivam 50 m 4 hrs S 15 yrs no no IWMI prox RCA KC I  
partially 
success 
8 Dass 62 m 5 hrs  NS no no no AWMI prox LAD KC I  success 
9 Murthy 65 m 3 hrs  S no no no IWMI distal RCA KC II success 
10 Jayavel 45 m 6 hrs  S 20 yrs  no no AWMI prox LAD KC I  failure 
11 Adhikesavan 50 m 4 hrs  NS  20 yrs  5 yrs  no AWMI  prox LAD  KC I  failure 
12 Kamalakannan 35 m 7 hrs  S 15 yrs no no AWMI  prox LAD  KC II failure 
13 Shankar 35 m 9 hrs NS 15 yrs no no AWMI prox to D1, 
distal t S1  
KC II failure 
14 Lakshmi 55 f 10 hrs S no 4 yrs 4 
yrs 
IWMI  prox RCA KC I failure 
15 Sekar 49 m 5 hrs NS no 7 yrs 4 
yrs 
IWMI prox RCA KC I  success 
16 Premkumar 38 m 4 hrs NS 15 yrs no no IWMI prox RCA  KC I  success 
17 Sampath 44 m 8 hrs NS 20 yrs  no no IWMI prox RCA KC I  success 
18 Nagammal 70 f 6 hrs S  no no no AWMI prx LAD KC II  failure 
 Sl 
no Name Age Sex Window Lifestyle Smoking Diabetes Sht Type Anatomy 
Killip 
class Result 
19 Perumal 70 m 4 hrs S no 10 yrs 10 yrs AWMI prox LAD  KC II  failure 
20 Krishnan 23 m 3 hrs  NS no no no AWMI prox LAD KC I  failure 
21 
Raman 45 m 5 hrs NS 25 yrs no no AWMI 
prox to D1 
, distal t S1  KC II success 
22 Perumal 52 m 4 hrs S 25 yrs no no AWMI prox LAD KC I success 
23 Radha 78 f 7 hrs S no 2 yrs no IWMI prox RCA KC I success 
24 Sivaganam 66 m 4 hrs NS no no 2 yrs AWMI prox LAD KC II success 
25 
Govindhan 55 m 5 hrs NS 15 yrs no no AWMI 
distal t D1 
& S 1  KC I success 
26 
Esther 66 m 2 hrs NS 20 yrs  no no AWMI 
prox to D1 
, distal t S1  KC II success 
27 
Aasaiyammal 65 f 7 hrs S no no 
1 
month AWMI prox LAD KC I  success 
28 
Hyat Basha 60 m 1 hr S no no no LWMI prox LCX  KC I success 
29 Godhandan 53 m 3 hrs  NS 20 yrs  no no AWMI prox LAD KC II success 
30 Dhanalakshmi 47 f 3 hrs  S no 5 yrs  no IWMI prox RCA KC I  success 
31 Devi 26 f 3 hrs  S no no no AWMI prox LAD KC I success 
32 Vishwanathan 75 m 1 hr NS no no recent IWMI prox RCA KC I success 
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no Name Age Sex Window Lifestyle Smoking Diabetes Sht Type Anatomy 
Killip 
class Result 
33 
Mary 45 f 8 hrs S no no no AWMI 
prox to D1, 
distal t S1  KC II success 
34 Kasiyammal 65 f 8 hrs S no 5 yrs  no IWMI prox RCA  KC I  success 
35 Munusamy 53 m 3 hrs  NS no 5 yrs  no IWMI prox RCA  KC I success 
36 Pandiyan 57 m 2 hrs NS no no no AWMI prox LAD KC I  success 
             
37 
Valliyammal 57 f 7 hrs S no 5 yrs  
5 
yrs AWMI prox LAD KC II 
partially 
success 
38 
Sundar 53 m 2 hrs NS 20 yrs  no no AWMI 
prox to D1, 
distal t S1  KC I  success 
39 Vedhagiri 60 m 4 hrs S no no no AWMI prox LAD KC I success 
40 
Sadhadullah 58 m 12 hrs NS 15 yrs no 
5 
yrs AWMI prox LAD KC I  failure 
41 Lakshmi 45 f 3 hrs  S no no no IWMI distal RCA KC I  success 
42 Arputharaj 39 m 1 hr NS no 2 months  2 
mo
nths 
AWMI prox to D1 
, distal t S1  
KC I success 
43 
Narayanasamy 70 m 2 hrs S no no 
5 
yrs IWMI distal RCA KC I success 
44 
Nagalingam 48 m 3 hrs  NS no 2 yrs 
2 
yrs AWMI 
prox to D1, 
distal t S1  KC I  failure 
45 Gowri 60 f 5 hrs  S no no no AWMI prox LAD KC I  failure 
46 Selvaraj 50 m 6 hrs NS 20 yrs  no no IWMI prox RCA  KC I partially 
success 
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47 Srinivasan 65 m 4 hrs S 20 yrs  no no AWMI prox to D1, 
distal t S1  
KC II  success 
48 Deivasigamani 55 f 7 hrs S no 7 yrs no AWMI prox LAD KC II  success 
49 Unnamalai 65 f 3 hrs  S no no no IWMI  distal RCA KC I success 
50 Sasikumar  38 m 21/2 hrs NS 15 yrs no no IWMI prox RCA  KC I success 
51 Muniyammal 65 f 4 hrs S no no no IWMI prox RCA KC I success 
52 Sekar 48 m 3 hrs  NS no no no AWMI prox LAD KC I  success 
53 Kothandan 65 m 4 hrs S 20 yrs  5 yrs  no IWMI distal RCA KC I success 
54 Mari 65 m 1 hr NS no 4 yrs no AWMI prox LAD KC I failure 
55 Siva  35 m 2 hrs NS 15 yrs no no IWMI prox RCA KC I success 
56 
Shankar 45 m 4 hrs NS 15 yrs no no AWMI 
prox to D1 
, distal t S1  KC I  success 
57 Bhuvaneshwari 23 f 3 hrs  NS no no no AWMI prox LAD KC I  failure 
58 Dhanasekar 55 m 41/2 hrs S no 6 yrs no AWMI  prox LAD KC I  success 
59 
Premkumar 43 m 4 hrs NS 20 yrs  no no AWMI 
prox to D1 
, distal t S1  KC I success 
60 Krishnan 55 m 8 hrs NS no 10 yrs no AWMI prox LAD KC I  failure 
61 Kumar 47 m 1 hr NS 20 yrs  no no AWMI prox LAD KC I  failure 
62 Subramani 60 m 1 hr S 30 yrs no no IWMI prox RCA  KC I  success 
63 Jayaraman 45 m 21/2 hrs NS 15 yrs no no IWMI prox RCA KC I  success 
64 Anthony 65 m 4 hrs S 20 yrs  no 3 
yrs 
IWMI prox RCA  KC I  failure 
65 Kasthuri 40 f 3 hrs  S no no no AWMI prox LAD KC I  success 
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66 
Elangali 65 f 3 hrs  S no 10 yrs 
10 
yrs AWMI 
prox to D1 
, distal t S1  KC I  failure 
67 
Pitchai 47 m 3 1/2 hrs NS no no no AWMI 
prox to D1 
, distal t S1  KC I  failure 
68 
Panchacharam 67 m 2 hrs S no no no AWMI 
prox to D1 
, distal t S1  KC I  failure 
69 Lakshmiammal 60 f 10 hrs S no no no IWMI prox RCA KC I  success 
70 
Jayakumar 60 m 8 hrs NS no 3 yrs 
8 
yrs IWMI distal RCA KC I  success 
71 
Rajagopal 58 m 2 hrs NS 18 yrs no 
2 
yrs IWMI distal RCA KC I  success 
72 
Vishwanathan 54 m 10 hrs NS 20 yrs  no 
5 
yrs IWMI Prox RCA KC I success 
73 Thangaraj 55 m 2 hrs NS 20 yrs  no no IWMI prox RCA KC I  success 
             
74 Arulanantham 57 m 11/2 hrs NS 10 yrs no no AWMI prox LAD KC II  success 
75 Sundaram 54 m 3 hrs  NS no 6 months no AWMI prox LAD KC II success 
76 
Govindaraj 70 m 9 hrs S no no no AWMI 
prox to D1 
, distal t S1  KC II failure 
77 
Varadhan 40 m 2 hrs NS no 10 yrs no AWMI 
prox to D1 
, distal t S1  KC I failure 
78 
Raji 70 f 6 hrs S no no no AWMI 
prox to D1 
, distal t S1  KC I  failure 
79 Rahmanabullah 76 m 2 hrs S no no no IWMI prox RCA  KC I  success 
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80 
Chinnadurai 55 m 3 hrs  NS 15 yrs no no AWMI 
prox to D1 
, distal t S1  KC I success 
81 
Venkatraman 52 m 1 hr NS no 6 yrs no AWMI 
prox to D1 
, distal t S1  KC I success 
82 
Pandian 61 m 7 hrs S no 3 yrs 
3 
yrs AWMI prox LAD KC I  failure 
83 
Govindhammal 48 f 11 hrs S no 5 yrs  no 
AW & 
IWMI 
Triple 
vessel 
disease KC II failure 
84 
Eswari 65 f 3 hrs  S no 10 yrs 
10 
yrs IWMI prox RCA KC I  success 
85 Vijayaraghavan 45 m 7 hrs NS 25 yrs no no AWMI prox LAD KC I  failure 
86 
Munusamy 63 m 5 hrs S no 7 yrs 
2 
yrs IWMI prox RCA KC I success 
87 Vinodhkumar 55 m 4 hrs NS 20 yrs  8 months no AWMI prox LAD KC II failure 
88 Ramasamy 67 m 31/2 hrs S no no no AWMI prox LAD KC I failure 
89 Sudhakar 35 m 1/2 hr NS 10 yrs no no IWMI prox RCA  KC I  success 
90 
Sekar 55 m 10 hrs NS no no 
7 
yrs AWMI prox LAD KC I failure 
91 Pazhiniammal 62 f 4 hrs S no 10 yrs no IWMI  distal RCA KC I  failure 
92 
Muthu 32 m 4 hrs NS 15 yrs no no AWMI prox LAD  KC II 
partially 
success 
93 Ravi 45 m 31/2 hrs NS 15 yrs 1 yr no LWMI LCX KC I  success 
94 Perumal 40 m 21/2 hrs NS 15 yrs no no AWMI prox LAD KC I success 
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95 
Krishnapa 55 m 41/2 hrs NS 30 yrs no no IWMI prox RCA KC I  
partially 
success 
96 Malliga 60 f 21/2 hrs S no 4 yrs no IWMI distal RCA KC I  success 
97 
Balaraman 73 m 10 hrs S 40 yrs no no AWMI 
prox to D1, 
distal t S1  KC I  failure 
98 Ramasamy 65 m 41/2 hrs S 25 yrs no no AWMI prox LAD KC II failure 
99 Vinayagamurthy 32 m 2 hrs NS 10 yrs no no AW & 
IWMI 
Triple 
vessel 
disease 
KC II success 
100 Shanmugam 35 m 31/2 hrs NS 5 yrs no no AWMI prox LAD KC I  success 
101 Aarifa 45 f 1 hr NS no 5 yrs  no IWMI prox RCA  KC I  success 
102 Veerabadhran 55 m 11/2 hrs NS no no no AWMI prox LAD KC I success 
 
